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Abstract
COMPLEXITIES OF CHRONIC OPIOID EXPOSURE

By Maciej Gonek, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.

Virginia Commonwealth University, 2018

Mentor: Dr. William L. Dewey, Chairman Pharmacology & Toxicology

Studies on repeated exposure to opioids have been carried out for decades yet the
mechanisms for certain phenomena such as tolerance are still not fully understood. Furthermore,
different medications, such as frequently prescribed benzodiazepines, or different disease states,
such as HIV, have their own effects and interactions with chronic opioid exposure that are not fully
understood. The overall objective of this dissertation was to investigate the complexities of chronic
opioid exposure and how different disease states and medications may modulate the effects of
chronic opioids. Our findings demonstrate that the administration of diazepam, at doses that are
not antinociceptive or have any motor effects, reverse both antinociceptive and locomotor
tolerance to orally active opioids. These doses of diazepam did not potentiate the acute effects of
these prescription opioids. We also found that HIV-1 Tat expression significantly attenuated the
antinociceptive potency of acute morphine in non-tolerant mice while not significantly altering the
antinociceptive tolerance to morphine. Consistent with this, Tat attenuated withdrawal symptoms
among morphine-tolerant mice. Pretreatment with maraviroc, a CCR5 antagonist blocked the
effects of Tat, reinstating morphine potency in non-tolerant mice and restoring withdrawal

xi

symptomology in morphine-tolerant mice. Protein array analyses revealed only minor changes to
cytokine profiles whether morphine was administered acutely or repeatedly; however, 24 h post
repeated morphine administration, the expression of several cytokines was greatly increased. Tat
further elevated levels of several cytokines and maraviroc pretreatment attenuated these effects.
With the understanding that gap junctions may be involved in both HIV-Tat effects on opioid
antinociception as well as tolerance, we investigated the role of gap junctions in opioid
antinociceptive tolerance. We observed that carbenoxolone, a gap junction inhibitor, administered
systemically attenuated the development of opioid antinociceptive tolerance. Furthermore, we
observed a small percentage of carbenoxolone in brain tissue compared to the amount found in
blood, suggesting a peripheral site of action. Finally, we show preliminary evidence that in vivo
administration of carbenoxolone is able to attenuate tolerance to morphine in DRG neurons.
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CHAPTER 1
INTRODUCTION
I. A History of Opioids
An ancient culture originating in southern Mesopotamia, modern day Iraq, the Sumerians
were the first in recorded history to cultivate what they called “hul gil”, or plant of joy around
3400 B.C. (Brownstein, 1993). The opium poppy (papaver somniferum) is species of plant from
which the dried latex opium can be extracted. Contained within that latex reside many alkaloid
compounds called opiates.
Although many used opium for religious ceremonies, medicinal purposes, as well as for
abuse, further understanding of opium’s effects occurred in 1805 after Friedrich Sertürner, a
German pharmacist, isolated the first active alkaloid in opium. He named it “morphium” after
Morpheus, the Greek god of dreams (Brownstein, 1993). Known today as morphine, it is the most
abundant opiate found within opium followed by codeine. When consumed orally, morphine was
found to be unreliable in its desired effects due to poor oral bioavailability. Following the invention
of the hypodermic needle and syringe, morphine quickly became a useful analgesic for use in
surgical procedures and postoperative pain. It was quickly discovered, however, that morphine
still shared opium’s additive properties as well as its undesirable side effects. Chemists took it
upon themselves to search for safer opioid compounds; opioids that are efficacious but are nonaddicting.
This led to a new generation of semi-synthetic opioid compounds that were orally bioactive
with similar properties to morphine, alas including addictive properties. In 1917, oxycodone was
synthesized from thebaine, another alkaloid found in opium. The synthesis of hydrocodone from
codeine was followed shortly in 1920. Both of these compounds can be considered opiates since
they are structurally similar to naturally occurring opium compounds. Opiates fall under the
1

general class of “opioid” compounds which include a broad spectrum of drug molecules that have
morphine-like agonist activity, which can be structurally similar or dissimilar from traditional
opiates and may be either naturally occurring or synthesized (Kreek et al., 2005).
Both oxycodone and hydrocodone were synthesized in the early part of the 20th century.
Yet, they would not be approved as pain reliving medications in the United States until more than
20 years after their discovery. Many in the United States remembered the promises of heroin (an
acetylated form of morphine) being advertised as a non-addictive morphine substitute. In 1963,
California’s attorney general estimated that oxycodone abuse made up one-quarter of all drug
addiction in the state. Top executives at the company who marketed the drug disputed this claim
and stated that the analgesic possessed “relatively little or no addicting liability” (Meier, 2003).
This pattern continued to repeat with Purdue Pharma L.P. who began marketing oxycodone in the
mid-1990s as a safer and appropriate compound for the relief of acute and chronic pain. Around
this time, there was growing concern regarding the undermanagement of pain. Therefore, in his
1995 Presidential Address to the American Pain Society, Dr. James Campbell presented the idea
of pain being the “fifth vital sign” (Campbell, 1996). Even though it cannot be measured
objectively like other vital signs (e.g. blood pressure, heart rate, etc.), the idea rapidly spread and
was adopted by the Veterans’ Health Administration (Booss et al., 2000). Although the Joint
Commission on Accreditation of Healthcare Organizations maintains that they never stated that
pain needed to be treated like a vital sign, they did suggest making it a patient rights issue and
emphasized the quantitative aspects of pain such as placing it on a 10-point scale (Phillips and
Chapman, 2000). These guidelines aided the perception that pain was undertreated and provoked
the overprescription of opioid painkillers.
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The amount of prescription opioids sold to pharmacies, hospitals, and doctors’ offices
nearly quadrupled from 1999 to 2010 (Paulozzi et al., 2011). Yet there had not been an overall
change in the amount of pain that Americans reported (Daubresse et al., 2014). With this fuel, the
U.S. opioid epidemic exploded with the number of overdose deaths involving opioids (including
prescription opioids and heroin) being 5 times higher in 2016 than in 1999. As of 2016, an average
of 115 Americans die every day from an opioid overdose (Rudd et al., 2016). Not all opioid users
started with opioid prescription analgesics. However, a 2014 study found 75 percent of heroin
users in treatment started with prescription opioids (Cicero et al., 2014). Furthermore, in 2015 the
CDC observed people who are addicted to prescription opioids are 40 times more likely to be
addicted to heroin. However, limited research has been done with these drugs when compared to
the opioid standard, morphine, and the illicit heroin. It is common to assume that these opioids all
act through a similar mechanism. However, these compounds have been shown to have different
pharmacokinetic properties, varying affinities for the μ opioid receptor, and have different offtarget effects (Nielsen et al., 2007). They are different molecules and it is disadvantageous and
maybe dangerous to assume they all act through the same mechanism. Therefore, it is important
to properly investigate how commonly prescribed opioids compare in their effects as opposed to
morphine.

II. Opioid Receptors & Opioid Pharmacology
Comprehending the mechanisms of how opioids induce their powerful effects has been a
goal for many pharmacologists. The idea being that understanding these mechanisms may one day
lead to a compound that lacks side effects. After the discovery of many opioid compounds, the
structure–activity relationships from the vast number of opioid derivatives led to the concept of
the opioid receptors (Portoghese, 1965). Among the early neurotransmitter receptors found were
3

opioid receptors which was quickly followed by the proposal and eventual discovery of
endogenous opioid peptide ligands. These peptide compounds are organized into one of three
families: the enkephalins, endorphins, and dynorphins. These peptides arise from much larger
precursor proteins called proenkephalin, proopiomelanocortin, prodynorphin, respectively.
Followed by the discovery of different classes of ligands, multiple opioid receptor types were
immediately suggested. The existence of specific opioid receptors in the central nervous system
was proposed after studies in the chronic spinal dog model (Martin et al., 1976). The existence of
μ, δ, and κ opioid receptors was ultimately confirmed and characterized using selective radioactive
ligands, cross tolerance studies, and the cloning of each receptor subtype (Chang et al., 1979;
Chang and Cuatrecasas, 1979; Evans et al., 1992; Kieffer et al., 1992; Meng et al., 1993; Porreca
et al., 1982; Schulz et al., 1980; Thompson et al., 1993)
Opioids play a role in the modulation of pain, affective behavior, locomotor activity,
learning and memory, neuroendocrine function, autonomic function, and immune function.
Primarily used as analgesics, opioids are also used clinically as antitussives and antidiarrheals.
Noxious effects include nausea, constipation, and respiratory depression, the cause of many opioid
overdose deaths. Opioids tend to have euphoric, rewarding properties that can cause people to
abuse them and over time become addicts.
Commonly used opioid drugs exert nearly all of their clinically relevant actions through
stimulation of the μ-opioid receptor (MOR). Activation of MORs by an agonist such as morphine
can cause analgesia, euphoria, sedation, nausea, respiratory depression, miosis, and constipation.
The multiple effects throughout the body may be explained by MORs being highly concentrated
in certain peripheral and central areas of the nervous system. In terms of antinociception, opioid
receptors are expressed in pain-modulating descending pathways, which include the
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periaqueductal gray (PAG) and the rostroventral medulla (RVM). They are also expressed in
limbic, midbrain, and cortical structures (Al-Hasani and Bruchas, 2011) These multiple sites of
opioid action have been deduced from the effects of local agonist and antagonist infusion.
The most common understanding of the mechanism of acute opioid administration is the
inhibitory effects on pain transmission. Opioid receptors, including MORs, are members of the G
protein-coupled receptor (GPCR) superfamily characterized by the presence of 7 transmembrane
regions. MORs are primarily considered to be part of Gi/o class of GPCRs, characterized by the
ability of the receptor to activate Gi alpha subunit, inhibiting adenylate cyclase activity thereby
lowering cAMP levels. The inhibition of adenylyl cyclase and the further inhibition of ion channels
are commonly accepted as the mechanism by which opioids block pain transmission. When
activated, MORs produce hyperpolarization of neurons (primarily through the activation of
potassium ion channels yielding an efflux of potassium ions) and the inhibition of calcium ion
channels, decreasing the transmission of neurotransmitters or nociceptive information (Fornasari,
2012; Williams et al., 2013).
III. Tolerance(s)
Repeated exposure to opioids is now more common than ever before. This observation is
seen in the clinic with enough opioid analgesics sold in 2010 to medicate every American adult
with a typical dose every 4 hours for 1 month (Paulozzi et al., 2011). This is also seen in the rising
abuse of opioids with 2 million Americans having a substance use disorder involving prescription
opioids and 591,000 using heroin (Center for Behavioral Health, 2016). Chronic exposure to
opioids exhibit different issues than short term, acute exposure. One common issue that arises after
repeated opioid exposure is tolerance.
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Tolerance is generally defined as a reduction or loss of responsiveness to an agonist after
continued exposure. Tolerance has been often studied in either the whole animal where the cellular
and molecular mechanisms are difficult to determine or in isolated tissues which may make
translational conclusions difficult. Typically, tolerance is measured as a rightward shift in the doseresponse curve that may also be associated with a reduction in the maximum response. Tolerance
after chronic exposure to opioids is commonly seen both in vivo and in vitro. Interestingly,
tolerance occurs to some, but not all opioid induced effects. Antinociception, respiratory
depression, and euphoria are all opioid effects susceptible to the development of tolerance. For
reasons still not fully understood, little to no tolerance is seen with opioid-induced constipation or
miosis (excessive pupillary constriction). It has been also shown that tolerance develops to these
different effects at different rates. Opioid tolerance development is fastest for the analgesic effects,
followed by respiratory depressant actions, and least for peripheral effects such as the slowing of
gastrointestinal motility (Dumas and Pollack, 2008; Hayhurst and Durieux, 2016; Hill et al., 2016).
Therefore, it is important to note that using the term tolerance to describe these generalities may
be somewhat of a red herring. In other words, using the general term tolerance to describe all of
these observed effects may be misleading because of the multiplicity of opioid tolerance
expression. A more accurate term may be the plural form, as opioid tolerances. Many mechanisms
have been discovered to underlie opioid tolerances. Despite intensive studies, neither the
mechanisms themselves nor the connections between them are fully understood.
Most studies have concentrated on the receptor level, with opioid receptors belonging to
the GPCR family. Consequently, opioid receptors are generally susceptible to a series of adaption
processes that occur in response to persistent GPCR activation. These adaption processes include
desensitization, internalization, and downregulation. Considered to be fairly rapid (seconds to
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minutes), desensitization is usually defined as the uncoupling of the receptor from its G-protein
and therefore a decrease in effector response. Mechanisms involved in desensitization may include
the activation of one or many kinase pathways which can lead to phosphorylation or binding to the
receptor. Intracellular kinases indicated in the phosphorylation of MORs include G protein
receptor kinases (GRKs), protein kinase C (PKC), protein kinase A (PKA), c-Jun N-terminal
kinases (JNKs), and many more (Williams et al., 2013). These kinases each contribute to their own
downstream signaling pathways. Downregulation refers to a reduced number of functional
receptors present in cells which occurs as a result of increased degradation and/or reduced
biosynthesis of receptors (Tsao and Zastrow, 2000; Williams et al., 2013).
Tolerance may occur differently depending on what opioid compound the MOR is exposed
to. Different agonists may initiate different receptor conformations and different downstream
signaling pathways. High efficacy agonists, such as the peptide [D-Ala2, N-MePhe4, Gly-ol]enkephalin (DAMGO) have been observed to produce tolerance through internalization and
downregulation of MOR through GRKs and β-arrestin (Stafford et al., 2001). However, partial
agonists such as morphine do not lead to internalization, as tolerance seems to be driven more by
desensitization, which may be driven primarily by PKC-mediated phosphorylation, although PKA
has been implicated as well (Bailey et al., 2009, 2006; Dalton, 2005; Hull et al., 2010).
The issue of tolerance continues to be more complex due to differences observed in cell
and tissue types. For example, morphine fails to induce MOR internalization in spinal cord in vivo
but it efficiently induces endocytosis in dendrites of nucleus accumbens neurons (Haberstockdebic et al., 2005, 2003; Trafton and Basbaum, 2004; Williams et al., 2013). It is argued that this
may be due to different isoforms of select kinases involved in opioid tolerance present in different
cell types. However, recent evidence shows different subtypes of MORs may also play an
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important role in opioid-mediated effects and may play a role in tolerance, specifically crosstolerance (Pasternak, 2010; 2018).
Preclinical and clinical studies have shown that tolerance to opioid-mediated effects are
susceptible to reversal by a number of agents. In the clinic, anesthesiologists reported having to
use less opioid medications for patients that were previously administered ketamine (Trujillo and
Akil, 1991). Recent publications that investigated the issue of polydrug abuse observed reversal
of opioid antinociceptive and respiratory depressive tolerance after the administration of ethanol
or diazepam (Gonek et al., 2017; Hill et al., 2016; Hull et al., 2013; Jacob et al., 2017). The list of
compounds that can reverse or attenuate opioid tolerances could be expanded to include different
kinase inhibitors, antibiotics, gap junction inhibitors, astrocyte inhibitors, and even the
administration of stem cells (Bailey et al., 2006; Dalton, 2005; Kang et al., 2017; Li et al., 2017,
2015; Shen et al., 2014; Smith et al., 1999). The sheer variety of agents that are able to attenuate
opioid tolerances highlight that opioid tolerance may not be explained by one cellular mechanism.
The underlying mechanisms of these and other reversal of opioid tolerances are poorly understood.
However, some key players emerge. Ketamine has many targets but it is primarily known as an
antagonist at NMDA receptors, which have been indicated as potential mechanism by which
opioid tolerance is reversed (Trujillo and Akil, 1991). Diazepam-induced reversal of morphine
antinociceptive tolerance was blocked by the GABAA antagonist bicuculline, suggesting that
GABAA receptors may play a role. However, ethanol-induced reversal of morphine
antinociceptive tolerance was not fully blocked by bicuculline as it required the administration of
both bicuculline and phaclofen, a GABAB antagonist (Hull et al., 2013). In a study investigating
ethanol reversal of morphine tolerance to respiratory depressive effects, an interaction involving
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PKC was proposed (Hill et al., 2016). Interestingly, activation of NMDA receptors are involved
with the activation of specific isoforms of PKC (Abraham, 2008; Lau and Zukin, 2007).
Many of these substances interact with inflammatory processes which have been observed
to interact with opioid tolerance. Increasing evidence suggests that opioids can also produce
neuroinflammatory responses in both central and peripheral nervous systems. Chronic morphine
treatment has been associated with increased astrocytic activity in several parts of the CNS and
increased the expression of proinflammatory cytokines TNFα, IL1-β and IL-6 (Shen et al., 2011;
Song and Zhao, 2001). Inhibiting these cytokines either by inhibiting glial cells release of them or
by directly preventing their interaction with receptors attenuates the development of opioid
tolerance (Shen et al., 2011). Chemokines, small cytokines secreted by cells that have the ability
to induce directed chemotaxis in nearby responsive cells, are also modulated by morphine
exposure within the central nervous system. The blockade of chemokine receptor CX3CR1
attenuated the development of antinociceptive tolerance and allodynia to chronic morphine
(Johnston et al., 2004). Activation of C-C Chemokine receptor type 5 (CCR5) can lead to crossdesensitization of MOR by phosphorylation by intracellular kinases (Szabo et al., 2003, 2002;
Zhang et al., 2004).
IV. Scope of Dissertation and Aims
The overall objective of this dissertation was to investigate the complexities of chronic
opioid exposure and how different disease states and medications may modulate the effects of
chronic opioids. We decided to primarily focus on opioid tolerances because this phenomena plays
an important role in the clinic (patients) and society (addicts) as a whole. The studies described
here lead to new understandings of what occurs on a behavioral and cellular level during repeated
exposure to opioids.
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Our first series of experiments characterized the effect of diazepam, a commonly
prescribed and abused anti-anxiety medication, to reverse the tolerances to prescription opioids
oxycodone and hydrocodone. In the next series of experiments, we examined the intertwined
health epidemic of HIV and investigated the role of the CCR5 receptors in proinflammatory HIV1 Tat’s effects on morphine tolerance, dependence, and reward. Lastly, we investigated how the
blockade of gap junctions influence the development of tolerances to morphine on a behavioral
and cellular level.
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CHAPTER 2
REVERSAL OF OXYCODONE AND HYDROCODONE TOLERANCE BY DIAZEPAM
This chapter has been published in Brain Research (Maciej Gonek, Hamid I. Akbarali, Graeme
Henderson. William L. Dewey (2017) “Reversal Of Oxycodone And Hydrocodone Tolerance By
Diazepam”)

Summary
The Centers for Disease Control has declared opioid abuse to be an epidemic. Overdose
deaths are largely assumed to be the result of excessive opioid consumption. In many of these
cases, however, opioid abusers are often polydrug abusers. Benzodiazepines are one of the most
commonly co-abused substances and pose a significant risk to opioid users. In 2016, the FDA
required boxed warnings – the FDA’s strongest warning – for prescription opioid analgesics and
benzodiazepines about the serious risks associated with using these medications at the same time.
The point of our studies was to evaluate the interactions between these two classes of drugs. We
investigated whether diazepam adds to the depressant effects of opioids or does it alter the levels
of tolerance to opioids. In the present study, we have found that the antinociceptive tolerance that
developed to repeated administration of oxycodone was reversed by an acute dose of diazepam.
Antinociceptive tolerance to hydrocodone was also reversed by acute injection of diazepam;
however, a four-fold higher dose of diazepam was required when compared to reversal of
oxycodone-induced tolerance. These doses of diazepam did not potentiate the acute
antinociceptive effect of either opioid. The same dose of diazepam that reversed oxycodone
antinociceptive tolerance also reversed oxycodone locomotor tolerance while having no
potentiating effects. These studies show that diazepam does not potentiate the acute effect of
prescription opioids but reverses the tolerance developed after chronic administration of the drugs.
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1. Introduction
Reducing opioid overdose deaths is an important public health and drug policy goal. Much
of the current opioid epidemic can be attributed to the rise in use of prescription opioid pain
analgesics such as oxycodone and hydrocodone. These drugs have become widely prescribed, with
enough opioid analgesics sold in 2010 to medicate every American adult with a typical dose every
4 hours for 1 month. In the United States, at least half of all opioid overdose deaths involve a
prescription opioid (Paulozzi et al., 2011). The dangers of accidental opioid overdose are mainly
due to respiratory depressive effects. Chronic use of opioids results in the development of tolerance
(a decrease in pharmacologic response following repeated or prolonged drug administration) to
the analgesic, euphoric, and respiratory depressive effects. This leads to addicts and patients taking
higher doses in order to obtain the euphoric high or the analgesic effects, respectively. However,
it has been shown that tolerance to different effects of opioids do not occur at the same rate or to
the same extent (Hill et al., 2016). It has been suggested that, in man, tolerance to euphoria
develops to a greater extent than to respiratory depression (White and Irvine, 1999).
Opioid overdose deaths are largely assumed to result from excessive opioid administration
alone. However, opioid abusers are often polydrug users, consuming benzodiazepines, ethanol,
cocaine and/or gabapentoids along with opioid drugs. Benzodiazepines and ethanol have been
found to pose a significant risk to chronic opioid users, particularly in those taking methadone
(National Treatment Agency for Substance Misuse [NTA], 2007). The CDC has reported that
benzodiazepines were involved in 31% of opioid related drug poisoning deaths in recent years
(Chen et al., 2014). Benzodiazepines, ethanol, and opioids are all considered central nervous
system depressants and their effects may be additive or synergistic. Recently, our lab has published
that low doses of ethanol and diazepam, which have no observable effect of their own, significantly
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and dose-dependently reduced the antinociceptive tolerance produced by morphine while not
affecting the acute responses (Hull et al., 2013). Low doses of ethanol reversed morphine tolerance
at the level of single brain neurons (Llorente et al., 2013) and in a rodent model of respiratory
depression (Hill et al., 2016).
A major limitation of the previously described studies is that they have not investigated
oxycodone and hydrocodone, two commonly prescribed opioid analgesics. Limited research has
been done with these drugs when compared to the opioid standard, morphine, and the illicit
compound heroin. Although all are considered opioids, these compounds may differently interact
through the μ opioid receptor (MOR). They have been shown to have different pharmacokinetic
properties, varying affinities for the μ opioid receptor, potentially interact with other opioid
receptors and have different off-target effects (Nielsen et al., 2007). Therefore, it is important to
investigate how commonly prescribed opioids compare in their effects to morphine.
The goals of this study were to determine if benzodiazepines potentiate the acute
antinociceptive effects of commonly prescribed opioids as well as to determine if they act to reduce
tolerance to these opioids. We characterized the development of antinociceptive tolerance to
oxycodone and hydrocodone in mice and investigated whether diazepam could reverse tolerance
as it does morphine-induced tolerance. Antinociception, as measured by the rodent warm water
tail-immersion assay, was chosen for these studies because it has been shown to be a good predictor
of antinociception and tolerance for a wide range of compounds in humans. Furthermore, our
group has used this assay to extensively investigate the mechanisms of opioid tolerance (Hull et
al., 2013, 2010; Smith et al., 2007).
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2. Experimental Procedure
2.1. Animals
Male Swiss Webster mice (Harlan Laboratories, Indianapolis, IN) weighing 25–30 g were housed
five to a cage in animal care quarters and maintained at 22 +/- 2°C on a 12-hour light-dark cycle.
Food and water were available ad libitum. The mice were brought to the test room (22 +/- 2°C,
12-hour light-dark cycle), marked for identification, and allowed 18 hours to recover from
transport and handling. Protocols and procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) at Virginia Commonwealth University Medical Center and comply
with the recommendations of the International Association for the Study of Pain (IASP).

2.2. Drugs and Chemicals
Oxycodone HCl and hydrocodone bitartrate were obtained from the National Institutes of
Health National Institute on Drug Abuse (Bethesda, MD) and were each dissolved in pyrogen-free
isotonic saline (Hospira, Lake Forest, IL). Diazepam was obtained from Sigma-Aldrich
Corporation (St Louis, MO, USA) and was dissolved in 45% hydroxypropyl beta-cyclodextrin
(HPBCD).

2.3. Antinociceptive Testing
Antinociception was assessed using the 56°C warm water tail immersion test performed
according to Coderre and Rollman (1983). Before injecting the mice, a baseline (control) latency
was determined. Only mice with a control reaction time from 2 to 4 seconds were used. The test
latency after opioid treatment was assessed at the peak time point of 20 minutes with a 10-second
maximum cut-off time imposed to prevent tissue damage. Antinociception was quantified
14

according to the method of Harris and Pierson (1964) as the percentage of maximum possible
effect (%MPE), which was calculated as: %MPE = [(test latency – control latency) / (10 – control
latency)]* 100. Percent MPE was calculated for each mouse.

2.4. Tolerance Studies
A 7 hour antinociceptive tolerance model for oxycodone and hydrocodone was developed.
Mice were injected subcutaneously (s.c.) once every hour for 7 hours (total of 7 injections) with
an acute ED80 dose of the opioid (1.25 mg/kg for oxycodone and 6 mg/kg for hydrocodone, as
previously determined). An hour after the final dose, mice were administered diazepam or vehicle
by intraperitoneal injection and 30 minutes later were challenged with subcutaneous doses of
oxycodone or hydrocodone to construct dose-response curves for calculation of ED50 values.. The
warm water tail immersion test was performed 20 minutes after the injection of the challenge dose
of opioid.
For maximum tolerance to oral administration of oxycodone, the route of administration
used by humans, a 4-day antinociceptive tolerance model was developed. Mice were orally
gavaged with 256 mg/kg oxycodone twice a day (9 AM & 5 PM) on day 1, 2, and 3. On the fourth
day, mice were gavaged only in the morning. A full 24 hours after their last pretreatment dose,
baseline latencies were recorded and immediately afterwards diazepam or vehicle was
administered by intraperitoneal injection. 30 minutes later, mice were challenged with oral doses
of oxycodone to construct dose-response curves for calculation of ED50 values. The warm water
tail immersion test began 20 minutes after the administration of the challenge dose.
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2.5. Locomotor Activity
Spontaneous motor activity was assessed using activity chambers (Med Associates, St.
Albans, VT). Each individual activity chamber has closeable doors and a ventilation system. The
interior of the chamber consists of a 27 × 27 cm Plexiglas enclosure that is wired with photo-beam
cells connected to a computer console that counts the activity of the animal contained within the
enclosure. For locomotor tolerance, a 4-day antinociceptive tolerance model was developed where
mice were orally gavaged with 64 mg/kg oxycodone twice a day (9 AM & 5 PM) on day 1, 2, 3,
and 4. On the fifth day, mice were habituated to the chamber for 30 minutes before any drug
administration. Afterwards, mice were administered an intraperitoneal injection of vehicle or 0.5
mg/kg diazepam and placed in home cage. 30 minutes later, mice were administered 64 mg/kg
oxycodone by oral gavage. 10 minutes later, mice were placed in separate activity chambers.
Ambulatory counts for spontaneous activity were obtained over a 40-minute time period.

2.6. Statistical Analysis
Opioid dose-response curves were generated for calculation of ED50 values using leastsquares linear regression analysis followed by calculation of 95% confidence limits (95% CL) by
the method of Bliss (Bliss, 1967). Significance was determined by non-overlapping 95%
confidence limits. Locomotor data was represented as mean ± standard error of the mean.
Locomotor data was analyzed using two-way analysis of variance (ANOVA) with factors for time,
treatment, and their interactions with locomotor activity followed by Tukey’s post hoc analyses to
determine statistical significance (Prism 6). Analyses were considered significant when p < 0.05.
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3. Results
3.1. Effects of Acute Diazepam in Drug-Naïve Mice
Diazepam was administered at doses of 0.5, 1, and 2 mg/kg i.p. and mice were monitored
over a 3-hour period for behavioral changes and assessed in the warm-water tail immersion test at
30-minute intervals over 2 hours. No antinociceptive effects or behavioral changes, including
locomotor activity, were observed at any of these doses.

3.2. Tolerance Development to Oxycodone
Baseline latencies were taken prior to the beginning of the hourly subcutaneous injections.
Mice were randomly assigned to either a chronic saline or chronic opioid schedule whereby seven
hourly injections of isotonic saline or an ED80 dose of oxycodone were given s.c. After seven
injections, mice were injected with a challenge dose of oxycodone (0.25, 0.5, 1, 2 or 4 mg/kg) at
the 8-hour time point (Figure 1). Dose-response curves for oxycodone after chronic injections of
saline generated similar ED50 values to those in acute dose response experiments (1.19 mg/kg
(1.00-1.41, 95% CL)). The ED50 was significantly shifted to the right 1.6-fold, indicating
tolerance was observed, in the animals chronically injected with oxycodone prior to receiving the
challenge injections (1.84 mg/kg (1.58 - 2.14, 95% CL)). The sample size of each group was 20
animals [Acute Oxycodone, n =20; Chronic Oxycodone, n = 20].

3.3. Reversal of Oxycodone Antinociceptive Tolerance with Diazepam in Tail Immersion
Assay
Baseline latencies were obtained in the tail immersion test in the morning before any
injections. Following the development of tolerance (single day tolerance model), diazepam (0.5
mg/kg i.p.) was administered. Thirty minutes later, the mice were challenged with doses of
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oxycodone s.c. for construction of dose-response curves for calculation of the ED50 values (Figure
1; Table 1). Diazepam fully reversed the oxycodone-induced tolerance. The sample size of each
group was between 10–20 animals [Acute Oxycodone, n =20; Chronic Oxycodone, n= 20; Chronic
Oxycodone + 0.5 mg/kg DZ, n= 12]. The same dose of diazepam did not potentiate the
antinociception produced by acute doses of oxycodone in naive mice (Figure 2) [Acute
Oxycodone, n =20; Acute Oxycodone + 0.5 mg/kg DZ, n= 11].

Table 1: Diazepam Reversal of Oxycodone Tolerance
Treatment
Oxycodone ED50
(mg/kg (95% C.L.))
Acute Oxycodone + Vehicle
1.19 (1.00-1.41)
Acute Oxycodone + Diazepam (0.5 mg/kg)

1.25 (1.04-1.50)

Chronic Oxycodone + Vehicle

1.84 (1.58-2.14)*

Chronic Oxycodone + Diazepam (0.5 mg/kg)

1.12 (0.88-1.43)

* Significantly different than Acute Oxycodone + Vehicle group based on non-overlapping 95%.

3.4. Tolerance Development to Hydrocodone
Baseline latencies were taken prior to the beginning of hourly subcutaneous injections. Mice were
assigned randomly to either a chronic saline or chronic opioid schedule whereby seven hourly
injections of isotonic saline or an ED80 dose of hydrocodone were given s.c. After seven injections,
all mice were injected with final challenge doses of hydrocodone (1, 2, 4, 8, 16 or 32 mg/kg) at
the 8-hour time point (Figure 3). Dose response curves of hydrocodone after chronic injections of
saline generated similar ED50 values to those in acute dose response experiments (5.51 mg/kg
(4.97-6.12, 95% CL)). The ED50 was significantly shifted 2.4-fold to the right in the animals
chronically injected with hydrocodone prior to receiving the challenge injections (13.18 mg/kg
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(11.00-15.80, 95% CL)). The sample size of each group was between 6–12 animals [Acute
Hydrocodone, n =6; Chronic Hydrocodone, n= 12]
3.5. Reversal of Hydrocodone Antinociceptive Tolerance with Diazepam in Tail Immersion
Assay
Baseline latencies were obtained in the tail immersion test in the morning before any
injections. Following the development of tolerance (single day tolerance model), diazepam was
administered i.p. Thirty minutes later, the mice were challenged with doses of hydrocodone s.c.
for construction of dose-response curves for calculation of the ED50 values (Table 2). In contrast
with oxycodone, 0.5 mg/kg diazepam did not fully reverse antinociceptive tolerance to
hydrocodone (Figure 3). 2 mg/kg diazepam fully reversed hydrocodone tolerance and actually
significantly potentiated the antinociceptive effect of hydrocodone after chronic administration
(Figure 4). However, 2 mg/kg diazepam did not potentiate the antinociception produced by an
acutely administered dose of hydrocodone (Figure 5). The sample size of each group was between
6–12 animals [Figure 3: Acute Hydrocodone, n =6; Chronic Hydrocodone, n= 12; Chronic
Hydrocodone + 0.5 mg/kg DZ n = 8; Figure 4: Acute Hydrocodone, n =12; Chronic Hydrocodone,
n= 12; Chronic Hydrocodone + 2 mg/kg DZ n = 6; Figure 5: Acute Hydrocodone, n =12; Acute
Hydrocodone + 2 mg/kg DZ n = 6].
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Table 2: Diazepam Reversal of Hydrocodone Tolerance
Treatment
Hydrocodone ED50
(mg/kg (95% C.L.))
Acute Hydrocodone + Vehicle
5.51 (4.97-6.12)
Acute Hydrocodone + Diazepam (2 mg/kg)

4.48 (3.22-6.25)

Chronic Hydrocodone + Vehicle

13.18 (11.00-15.80)*

Chronic Hydrocodone + Diazepam (0.5 mg/kg)

9.92 (7.74-12.70)*

Chronic Hydrocodone + Diazepam (2 mg/kg)

3.77 (2.83-5.04)

* Significantly different than Acute Oxycodone + Vehicle group based on non-overlapping 95%.

3.6. Reversal of Oral Oxycodone Antinociceptive Tolerance with Diazepam in Tail
Immersion Assay
Following the development of maximum tolerance (4-day oral tolerance model), diazepam
was administered i.p. Thirty minutes later, the mice were challenged with doses of oxycodone p.o.
for construction of dose-response curves for calculation of the ED50 values. The ED50 of the acute
oral oxycodone was 8.33 (5.77-12.03, 95% CL). There was marked tolerance to oral oxycodone
following the 4-day oral tolerance model. The observation that 0.5 mg/kg diazepam was able to
fully reverse the antinociceptive tolerance to oral oxycodone (Figure 6) was supported by the
overlapping ED50: 13.24 mg/kg (4.00 - 43.93, 95% CL). Administering 0.5 mg/kg diazepam to
animals given acute oral oxycodone generated the ED50 value of 7.27 mg/kg (5.01 - 10.54, 95%
CL), indicating that it did not potentiate the antinociception produced by acute doses of oxycodone
(Figure 7). The sample size of each group was between 6-7 animals [Figure 6: Acute Oral
Oxycodone, n =6; Chronic Oral Oxycodone, n= 7; Chronic Oral Oxycodone + 0.5 mg/kg DZ n =
6; Figure 7: Acute Oral Oxycodone, n =6; Acute Oral Oxycodone + 2 mg/kg DZ n = 6].
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3.7. The Lack of the Development of Antinociceptive Tolerance to Oral Hydrocodone in Tail
Immersion Assay
We attempted a model to produce tolerance to oral hydrocodone in the tail immersion
assay. A dose response curve of acute oral hydrocodone was established and reliably repeated.
However, we did not succeed in developing tolerance to oral gavages of hydrocodone (data not
shown). Methods to establish such a model included a 4-day antinociceptive tolerance model using
a twice a day dosing schedule of 32, 64, 128, or 256 mg/kg.

3.8. Development of Locomotor Tolerance to Oral Oxycodone and Subsequent Reversal with
Diazepam
Tolerance was examined by assessing changes of locomotor activity after acute and
repeated oxycodone gavages. A main effect was noted for treatment group [F (3,15) = 5.49, p <
0.001] , time [F (7,105) = 10.89, p < 0.0001], and treatment × time interaction [F (21,105) = 4.29,
p < 0.001]. Post hoc tests demonstrated acutely administered 64 mg/kg oral oxycodone produced
significant increased ambulatory counts starting from 20 minutes (with the exception at the 25minute time point) until the 40-minute endpoint (Figure 8). Using a modified 4-day oral tolerance
model, tolerance to oxycodone’s stimulatory effects was observed. After the administration of 0.5
mg/kg diazepam to mice that were repeatedly treated with oral oxycodone, 64 mg/kg oral
oxycodone produced significant increased ambulatory counts starting from the 35-minute time
point until the 40-minute endpoint. In determining the effects of acute diazepam by itself or on
acute oxycodone’s stimulatory effects, a two-way ANOVA revealed a main effect for treatment
group [F (3,16) = 9.37, p < 0.001] , time [F (7,112) = 34.62, p < 0.0001], and treatment × time
interaction [F (21,112) = 10.42 , p < 0.001]. Post hoc tests revealed that 0.5 mg/kg diazepam did
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not potentiate acute oxycodone’s stimulatory effects in the locomotor assay. This dose of diazepam
did not show any stimulatory effects on its own (Figure 9). The sample size of each group was five
animals with the exception of the chronic oxycodone group with four animals.
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Fig. 1. Tolerance to oxycodone, developed using a single-day injection paradigm, was
significantly reversed by 0.5 mg/kg diazepam (n = 10–20). Latency to tail withdrawal (% MPE ±
SEM) among mice that were drug naïve, repeatedly treated with oxycodone, or repeatedly treated
with oxycodone and diazepam pretreatment 30 min before testing. Various doses of the oxycodone
were used for construction of dose-response curves for calculation of ED50 values.
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Fig. 2. 0.5 mg/kg Diazepam did not potentiate the antinociception produced by oxycodone in the
tail immersion test. (n = 10–20). Latency to tail withdrawal (% MPE ± SEM) among mice that
were drug naïve or pretreated with diazepam 30 min before testing. Various doses of the
oxycodone were used for construction of dose response curves for calculation of ED50 values.
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Fig. 3. 0.5 mg/kg Diazepam did not fully reverse the antinociception produced by hydrocodone in
the tail immersion test (n = 6–12). Latency to tail withdrawal (% MPE ± SEM) among mice that
were drug naïve, repeatedly treated with hydrocodone, or repeatedly treated with hydrocodone and
pretreated with diazepam 30 min before testing. Various doses of the hydrocodone were used for
construction of dose-response curves for calculation of ED50 values.
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Fig. 4. 2 mg/kg Diazepam fully reversed the antinociception produced by hydrocodone in the tail
immersion test (n = 6–12). Latency to tail withdrawal (% MPE ± SEM) among mice that were
drug naïve, repeatedly treated with hydrocodone or repeatedly treated with hydrocodone and
pretreated with diazepam 30 min before testing. Various doses of the hydrocodone were used for
construction of dose-response curves for calculation of ED50 values.
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Fig. 5. 2 mg/kg Diazepam did not potentiate the antinociception produced by hydrocodone in the
tail immersion test (n = 6–12). Latency to tail withdrawal (% MPE ± SEM) among mice that were
drug naïve or pretreated with diazepam 30 min before testing. Various doses of the hydrocodone
were used for construction of dose-response curves for calculation of ED50 values.
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Fig. 6. 0.5 mg/kg Diazepam fully reversed the antinociception produced by multiple-day paradigm
of oral oxycodone in the tail immersion test. (n = 6–7). Latency to tail withdrawal (% MPE ± SEM)
among mice that were drug naïve, repeatedly gavaged with oxycodone over 4 days, or repeatedly
gavaged with oxycodone over 4 days and pretreated with diazepam 30 min before testing. Various
doses of the oxycodone were used for construction of dose-response curves for calculation of ED50
values.

28

Fig. 7. 0.5 mg/kg Diazepam did not potentiate the antinociception produced by oxycodone (p.o.)
in the tail immersion test (n = 6). Latency to tail withdrawal (%MPE ± SEM) among mice that
were drug naïve or pretreated with diazepam 30 min before testing. Various doses of the
oxycodone were used for construction of dose response curves for calculation of ED50 values.
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Fig. 8. Locomotor stimulation in response to vehicle or oxycodone (64 mg/kg p.o.) was assessed
(n = 5). * Indicates a significant effect of acute oxycodone increasing ambulatory counts as
compared to mice naïve to the opioid (treated with vehicle). Indicates a significant effect of chronic
oxycodone + 0.5 mg/kg diazepam increasing ambulatory counts as compared to mice naïve to the
opioid (p < 0.05)
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Fig. 9. Locomotor stimulation in response to vehicle, diazepam (0.5 mg/kg i.p.) or oxycodone (64
mg/kg p.o.) was assessed (n = 5). * Indicates a significant effect of both acute oxycodone and acute
oxycodone + 0.5 mg/kg diazepam increasing ambulatory counts as compared to mice naïve to the
opioid (p < 0.05). 0.5 mg/kg diazepam does not potentiate acute oxycodone’s stimulatory effects.
0.5 mg/kg diazepam does not produce a difference in stimulatory counts when compared to naïve
controls.
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4. Discussion
Oxycodone and hydrocodone remain among the most commonly prescribed drugs for relief
of acute and chronic pain. However, tolerance limits the long-term utility of these opioid agonists,
leading to escalating doses of opioids to achieve the same analgesic effect while increasing the
risks for abuse liability and death from respiratory depression. Additionally, people who become
tolerant and then addicted to opioids usually are consuming other substances as well. Therefore, it
is imperative to investigate the effects of these other substances on opioid tolerance. In this study,
we investigated the effects of diazepam, a widely coabused substance, on oxycodone and
hydrocodone antinociceptive tolerance and oxycodone locomotor stimulating tolerance in mice.
We found that diazepam reversed the antinociceptive tolerance that developed after
repeated injections of subcutaneous oxycodone. The observation that an acute dose of diazepam,
that was inactive alone, reversed tolerance to the antinociceptive effects of oxycodone is in
agreement with our previous studies in which we demonstrated that diazepam reversed tolerance
to the antinociceptive effects of morphine (Hull et al., 2013). We also demonstrated that the same
dose of diazepam that reversed oxycodone tolerance did not significantly enhance the
antinociceptive effect of acute oxycodone.
Patients are often administered oxycodone in tablets or solutions intended for oral use.
Therefore, in a separate series of experiments, we investigated the ability of diazepam to reverse
maximum tolerance of oral oxycodone. In these studies, to achieve maximum tolerance, we
administered 256 mg/kg oxycodone orally twice a day for four days. Testing on the fifth day, this
protocol produced significant tolerance illustrated by the lack of effective doses as high as 64
mg/kg. The observation that 0.5 mg/kg diazepam was able to reverse this maximum tolerance
further supports the phenomenon of oxycodone tolerance reversal by benzodiazepines.
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Furthermore, we found that diazepam reversed the antinociceptive tolerance that developed
after repeated subcutaneous injections of hydrocodone. However, the reversal of tolerance to
hydrocodone required a larger dose of diazepam than needed to reverse oxycodone or morphine
tolerance. It is clear that diazepam did not potentiate the acute antinociceptive effect of
hydrocodone. Further investigation is needed into why diazepam reversed oxycodone and
morphine antinociceptive tolerance at lower doses than it reversed hydrocodone tolerance. It is
possible that this difference occurred because hydrocodone produced a greater amount of tolerance
than oxycodone. However, this is unlikely because the greatest tolerance was achieved using a
multiple day oral oxycodone model and this tolerance was reversed by 0.5 mg/kg diazepam.
Hydrocodone is also commonly administered to patients in tablets or solutions intended for oral
use. We were not able to achieve tolerance when hydrocodone was given orally. This can be due
to the fact that hydrocodone has been found to be less potent in certain measures of opioid effects
(Zacny and Gutierrez, 2009). However, it is uncertain as to why we observed a greater amount of
tolerance to repeated subcutaneous injections of hydrocodone compared to oxycodone yet no
significant tolerance to hydrocodone given repeatedly orally. Further studies are needed to
examine whether there is an important pharmacokinetic difference between oral dosing of
oxycodone and hydrocodone.
The interaction between benzodiazepines and opioids on antinociception has been reported
in the literature but with disagreement. Doses of diazepam, up to 5 mg/kg, were inactive in our
warm water tail-withdrawal assays. Several studies reported antinociception with diazepam
(Jiménez-Velázquez et al., 2010, 2008; Sierralta and Miranda, 1992). This difference may lie in
the different noxious stimuli used (chemical versus thermal) and route of administration
(intracerebroventricular injection versus intraperitoneal). In our studies, there was no potentiation
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of oxycodone or hydrocodone induced antinociception with pretreatment doses of diazepam up to
0.5 mg/kg and 2 mg/kg, respectively. Whereas in other studies, intrathecal administration of
benzodiazepines were found to enhance opioid antinociception (Bergman et al., 1988; Rattan et
al., 1991). In agreement with our studies, others found neither an antinociceptive effect of
benzodiazepines nor a potentiation effect of benzodiazepines on opioid induced antinociception
(Mantegazza et al., 1982; Rodgers and Randall, 1987; Rosland et al., 1990). To our knowledge,
benzodiazepines’ interaction with oxycodone or hydrocodone has not been previously
investigated.
In light of these results on antinociceptive tolerance, we tested the hypothesis that diazepam
will have a similar effect in another paradigm of tolerance. We observed that oxycodone increased
stimulatory activity in the locomotor activity assay. Marked tolerance was observed after repeated
exposure to oxycodone over four days. Diazepam significantly reversed this marked tolerance. To
rule out potentiation, we tested whether diazepam simply had an additive effect when combined
with oxycodone. Diazepam did not potentiate acute oxycodone’s stimulatory effects nor did it have
any stimulatory effects on its own. At this dose of diazepam, we did not detect either depressing
or stimulatory effects. Diazepam is classified as a CNS depressant and has been shown to decrease
locomotor activity (Spyraki and Papadopoulou, 1980). In certain cases (such as prolonged social
isolation), low doses of diazepam have been shown either to be inactive or have a stimulatory
effect, resulting in a bimodal dose response curve (Pinna et al., 2006). The similar reversal of
tolerance seen in both antinociception and in locomotor activity suggest that diazepam acts on a
mechanism of tolerance that is shared by both opioid-induced effects.
The precise mechanisms and neuronal circuitry involved remain to be elucidated. This
tolerance-reversal effect could be responsible, in part, for the high incidence of polydrug use
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among opioid abusers. It has been suggested that opioid abusers occasionally combine the use of
benzodiazepines with opioids to achieve a greater high (Jones et al., 2012). Whether this is simply
an additive or synergistic effect is not clear and in a previous publication, we have suggested that
compounds that act on GABA receptors increase the rewarding effects of opioid abuse by reducing
tolerance (Hull et al., 2013). It has been theorized that both benzodiazepines and opioids produce
a hyperpolarization of GABA interneurons which causes a reduction in the release of GABA which
results in the disinhibition of dopaminergic neurons and an increase in extracellular dopamine in
areas such as the striatum (Tan et al., 2011). The phenomenon of opioid-induced locomotion is
due to mu opioid receptor-mediated increases in striatal dopamine release (Johnson and Glick,
1993; Kalivas and Duffy, 1987; Piepponen et al., 1999). GABAergic interneurons also play an
important role in opioid antinociception (Lau et al., 2014). This suggests a potential site of action
that should be further examined.
Our observations suggest this phenomenon is not due to the additive or synergistic effects
of these CNS depressants but instead results from a reversal of tolerance. The result may be the
same but the mechanism should be considered as new understandings of the tolerance mechanism
will lead to new drug therapies such as tolerance-resistant analgesics. Similar reversal of opioid
tolerance has been observed in models of respiratory depression and at the single cell level (Hill
et al., 2016; Llorente et al., 2013). The reversant (reversing agent) in their studies was ethanol,
which along with benzodiazepines, interacts with GABAA receptors.
The neurochemical mechanism of this reversal is likely due to diazepam’s action on
GABAA receptors. Our laboratory demonstrated that the diazepam reversal of morphine tolerance
was fully inhibited by bicuculline, a GABAA antagonist, but not by phaclofen, a GABAB
antagonist. This was in contrast to ethanol as neither inhibitor fully reversed ethanol’s reversal or
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morphine tolerance until they were administered in combination (Hull et al., 2013). Future studies
should include determining whether the reversal of oxycodone and hydrocodone tolerance is due
to diazepam’s effects on GABAA receptors, if any subtypes are significant for the effect, and the
necessary intracellular pathways for this phenomenon.

5. Conclusion
Collectively, our findings demonstrate that the administration of diazepam, at doses that are not
antinociceptive or have any motor effects, reverses both antinociceptive and locomotor tolerance
to orally active opioids. These doses of diazepam did not potentiate the acute effects of these
prescription opioids. The findings reported here suggest that individuals who are taking oral
opioids for chronic pain relief and an anxiety agent such as diazepam need be cognizant of the risk
of reversal of tolerance to opioids that could lead to unintentional overdose deaths.
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CHAPTER 3
CCR5 MEDIATES HIV-1 TAT-INDUCED NEUROINFLAMMATION AND
INFLUENCES MORPHINE TOLERANCE, DEPENDENCE, AND REWARD
This chapter has been published in Brain, Behavior, and Immunity (Maciej Gonek, Virginia D.
McLane, David L. Stevens, Kumiko Lippold, Hamid I. Akbarali, Pamela E. Knapp, William L.
Dewey, Kurt F. Hauser, Jason J. Paris (2017) “CCR5 Mediates Hiv-1 Tat-Induced
Neuroinflammation And Influences Morphine Tolerance, Dependence, And Reward”)

Summary
The HIV-1 regulatory protein, trans-activator of transcription (Tat), interacts with opioids to
potentiate neuroinflammation and neurodegeneration within the CNS. These effects may involve
the C-C chemokine receptor type 5 (CCR5); however, the behavioral contribution of CCR5 on
Tat/opioid interactions is not known. Using a transgenic murine model that expresses HIV-1 Tat
protein in a GFAP-regulated, doxycycline-inducible manner, we assessed morphine tolerance,
dependence, and reward. To assess the influence of CCR5 on these effects, mice were pretreated
with oral vehicle or the CCR5 antagonist, maraviroc, prior to morphine administration. We found
that HIV-1 Tat expression significantly attenuated the antinociceptive potency of acute morphine
(2 – 64 mg/kg, i.p.) in non-tolerant mice. Consistent with this, Tat attenuated withdrawal symptoms
among morphine-tolerant mice. Pretreatment with maraviroc blocked the effects of Tat, reinstating
morphine potency in non-tolerant mice and restoring withdrawal symptomology in morphinetolerant mice. Twenty-four hours following morphine administration, HIV-1 Tat significantly
potentiated (~3.5-fold) morphine-conditioned place preference and maraviroc further potentiated
these effects (~5.7-fold). Maraviroc exerted no measurable behavioral effects on its own. Protein
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array analyses revealed only minor changes to cytokine profiles when morphine was administered
acutely or repeatedly; however, 24 h post morphine administration, the expression of several
cytokines was greatly increased, including endogenous CCR5 chemokine ligands (CCL3, CCL4,
and CCL5), as well as CCL2. Tat further elevated levels of several cytokines and maraviroc
pretreatment attenuated these effects. These data demonstrate that CCR5 mediates key aspects of
HIV-1 Tat-induced alterations in the antinociceptive potency and rewarding properties of opioids.

1. Introduction
There is a dynamic relationship between opioid use, human immunodeficiency
virus-1 (HIV-1) acquisition, and disease progression. Worldwide, injection drug use (IDU)
accounts for ~30% of new HIV-1 infections outside of sub-Saharan Africa (WHO, 2016). Within
the United States, over 3,500 new infections involved IDU in 2015 (CDC 2016), a year in which
overall drug overdose deaths rose another 11%, the majority (63%) of which involved opioids
(Rudd et al., 2016). The convergence of the HIV and opioid epidemics is particularly concerning
given evidence that opioid usage increases the progression of HIV-1 to acquired immune
deficiency syndrome (AIDS) and promotes neurocognitive impairment in humans and non-human
primates (Bell et al., 2006, 2002; Bokhari et al., 2011; Chuang et al., 2005; Donahoe et al., 1993;
Kumar et al., 2006; R et al., 2004; Rivera et al., 2013). Moreover, HIV-infected individuals are at
risk for the development of neuropathic pain (Malvar et al., 2015) for which prescription opioids
remain a common treatment (Kremer et al., 2016; Zilliox, 2017). Pharmacological treatment for
opioid

abuse

includes

substitution

therapies

(e.g.

methadone,

buprenorphine,

buprenorphine/naloxone; Moatti et al., 1998; Roux et al., 2008; Sambamoorthi et al., 2000; Woody
et al., 2014), which may exert neurotoxic interactions with HIV-1 proteins (Fitting et al., 2014b).
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As such, the mechanisms and physiological consequences of HIV/opioid interactions need to be
understood in order to improve outcomes for HIV seropositive patients that are pharmacologically
managed for pain and/or addiction.
The biological mechanisms that underlie HIV-1 and opioid interactions in the central
nervous system (CNS) likely involve the HIV-1 regulatory protein, trans-activator of transcription
(Tat). Tat is critical for efficient HIV replication; however, Tat is soluble and can be secreted from
infected cells to exert direct and indirect neurotoxicity in vitro (reviewed in King et al., 2006; Nath
et al., 2002). Tat promotes neuroinflammation via NF-κB signaling (El-Hage et al., 2008b; Herbein
et al., 2010), upregulation of proinflammatory cytokines [particularly the endogenous βchemokine ligands for the C-C “motif” chemokine receptor type 5 (CCR5): C-C chemokine ligand
3 (CCL3, also known as “macrophage inflammatory protein-1α” or MIP-1α), CCL4 (also known
as “macrophage inflammatory protein-1β” or MIP-1β), and CCL5 (also known as “regulated on
activation normal T-cell expressed and secreted” or RANTES); El-Hage et al., 2005; Hahn et al.,
2010]. And subsequent recruitment of neuroimmune cells promoting neuroinflammation In vitro,
morphine exacerbates Tat effects to activate microglia (Bokhari et al., 2009; Gupta et al., 2010;
Sorrell and Hauser, 2014), increase cytokine production (Bokhari et al., 2009; El-Hage et al., 2005;
Fitting et al., 2014b.; Turchan-Cholewo et al., 2009), drive oxidative stress (Dalvi et al., 2016;
Fitting et al., 2014a,b; Malik et al., 2011; Turchan-Cholewo et al., 2009), increase intracellular
calcium (El-Hage et al., 2005; Fitting et al., 2014a,b), and promote neurotoxicity (Fitting et al.,
2014a,b.; Gurwell et al., 2001; Malik et al., 2011). Morphine and Tat interactions may depend on
μ opioid receptors (MORs) given that neurotoxic synergy is observed in co-cultures when mixed
glia express MORs, but not when they are derived from MOR−/− mice (Zou et al., 2011). These
data support the notion that glial MORs are critical for the indirect neurotoxic effects of Tat.
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The proinflammatory effects of HIV-1 Tat at CCR5 may directly influence opioid
sensitivity. In studies of opioid-mediated antinociception in rats, activation of CCR5 or CXCR4
can rapidly (within 30 min) desensitize μ- or δ-opioid-receptors (Chen et al., 2007). Blocking
actions at CCR5 in proinflammatory states may attenuate heterologous desensitization of MORs
and increase therapeutic efficacy. In support, intrathecal administration of the CCR5 antagonist,
maraviroc, attenuated chronic constriction injury induced microgliosis, astrogliosis, upregulation
of CCR5 protein, and mRNA expression of CCR5-ligands (CCL3, CCL4, and CCL5) in the spinal
cord and dorsal root ganglion concurrent with reduced neuropathic pain (Kwiatkowski et al.,
2016). Moreover, CCR5 and MORs may form functionally active heteromers. A bivalent ligand
derived from a MOR agonist (oxymorphone) and a CCR5 antagonist (TAK-220) had ~2000×
greater antinociceptive potency than morphine in mice experiencing LPS-mediated inflammation
(Akgün et al., 2015). Another bivalent ligand comprised of an opioid receptor antagonist
(naltrexone) and maraviroc reduced the infectivity of human astrocytes when cultured with R5tropic HIV (Arnatt et al., 2016; El-Hage et al., 2013; Yuan et al., 2013). These data suggest a
dynamic relationship between MOR and CCR5 activation that may contribute to HIV pathology;
however, the functional effects are poorly understood. As such, we investigated morphine
tolerance, dependence, and reward in a transgenic murine model that conditionally-expresses the
proinflammatory HIV-1 regulatory protein, Tat1-86. Using a transgenic mouse approach,
conditional Tat expression has been demonstrated to reduce the antinociceptive potency of
morphine (Fitting et al., 2016, 2012), while potentiating psychostimulant reward in acute drug
withdrawal (24 h post drug administration; (Paris et al., 2014a,b). We hypothesized that HIV-1 Tat
expression would attenuate morphine antinociceptive potency and that the CCR5 antagonist,

40

maraviroc, would reverse these effects. Further, we hypothesized that 24 h post morphine, Tatand cytokine-mediated effects would be potentiated.

2. Materials and Methods
The use of mice in these studies was pre-approved by the Institutional Animal Care and
Use Committee at Virginia Commonwealth University and the experiments were conducted in
accordance with ethical guidelines defined by the National Institutes of
Health (NIH Publication No. 85-23).

2.1. Subjects and housing
Adult male mice expressed (or did not express) an HIV-1IIIB tat1-86 transgene (N = 245) as
previously described (Bruce-Keller et al., 2008; Fitting et al., 2013; Hauser et al., 2009) and were
generated in the vivarium at Virginia Commonwealth University (MCV campus). Briefly, HIV-1
Tat1-86 is conditionally expressed in a CNS-targeted manner via a GFAP-driven, Tet-on promoter
(activated by consumption of doxycycline-containing chow) in Tat(+) mice. Tat(-) control
littermates express the Tet-on transcription factor without the tat1-86 transgene. While Tat can
induce astrogliosis in transgenic mice (El-Hage et al., 2008b; Hahn et al., 2015; Paris et al., 2015),
this has not been observed to impair Tat production (Fitting et al., 2012; Paris et al., 2014b).
Additional control experiments were carried out in adult, male, C57BL/6J mice (N = 30). All mice
(~70 days of age) were housed 4 - 5 / cage and were maintained in a temperature- and humidity
controlled room on a 12:12 h light / dark cycle (lights off at 18:00 h) with ad libitum access to food
and water.
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2.2. Chemicals
To induce HIV-1 Tat1-86 expression, Tat(+) transgenic mice [and Tat(-) controls]
were placed on doxycycline chow (Dox Diet #2018, 6 g/kg; Harlan Laboratories, Madison, WI,
USA) for 28 days, unless otherwise specified. Some mice received subcutaneous implants of
placebo or morphine pellets (75 mg; National Institute on Drug Abuse, Rockville, MD, USA), the
latter of which induces tolerance and dependence in the present strain of mice (Fitting et al., 2016).
To precipitate morphine withdrawal, mice were administered (-)naloxone (1 mg/kg, s.c.; SigmaAldrich, St. Louis, MO; (Fitting et al., 2016). To investigate morphine reward, mice were
administered morphine sulfate (#M8777; Sigma-Aldrich) at a concentration of 10 mg/kg, i.p. (0.1
ml per 10 g body weight) which has been demonstrated to produce morphine-conditioned place
preference (CPP; Zhu et al., 2015). To investigate the contribution of CCR5 to these effects, some
mice were administered the CCR5-selective antagonist, maraviroc (62 mg/kg, p.o.; #376348-651; BOC Sciences, Shirley, NY, USA) which was dissolved in 100% DMSO, then diluted to 5%
DMSO in vegetable oil. Using inter-species allometric scaling (by a factor of 12.3; (Freireich et
al., 1966; Reagan-Shaw et al., 2008) others have determined maraviroc (62 mg/kg, p.o.) dosing
for mice from clinical formulations (Neff et al., 2010).

2.3. Surgical manipulation
Mice received subcutaneous implants of placebo or morphine (75 mg) pellets
under isoflurane (2.5 %) anesthesia as previously reported (Fitting et al., 2016; Ross et al., 2008).
Following surgery, mice were monitored to ensure weight gain, muscle tone, proper neurological
response, and general health (Crawley and Paylor, 1997). No mice failed to recover.
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2.4. Behavioral assays
Prior to all behavioral testing, mice were acclimated to the testing room for 24 h. For
assessments of morphine tolerance and morphine dependence, mice received subcutaneous
implants of placebo or morphine pellets. Five days later, mice were assessed for morphine
tolerance in a warm-water tail-withdrawal assay. Following tail withdrawal testing, mice
underwent naloxone-precipitated withdrawal and were assessed for morphine dependence. For
assessments of morphine reward, Tat-transgenic mice were assessed in a CPP paradigm with
psychomotor sensitization assessed on conditioning days. Some mice were additionally assessed
on a rotarod to rule out potential locomotor confounds.

2.4.1. Warm-water tail-withdrawal test
A warm-water tail-withdrawal test was conducted with a water-bath maintained at
56 ± 0.1°C as previously described (Coderre and Rollman, 1983; Fitting et al., 2016). Briefly, mice
were gently wrapped in a cloth and the distal one-third of the tail was immersed in a water bath.
The mice rapidly removed their tail from the bath at the first sign of discomfort and the tailwithdrawal latency was recorded. Tail-withdrawal latency was then assessed using a cumulative
dosing procedure. Mice were injected with a starting dose of morphine and were tested for
antinociception 20 min later. Mice that did not reach a 10 sec cut-off threshold received an
additional cumulative dose of morphine and were retested. This process was repeated until the
animals reached the cut-off value of 10 sec. Baseline latency ranged from 2 to 4 sec. The 10 sec
maximum cutoff latency was used to prevent tissue damage. Antinociception was quantified as the
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percentage of maximal possible effect (%MPE): %MPE = [(Test latency − Baseline latency) / (10
– Baseline latency)] × 100 (Harris and Pierson, 1964).

2.4.2. Antagonist-precipitated withdrawal
Mice were administered an injection of the opioid receptor antagonist, naloxone (1
mg/kg, s.c.), in order to precipitate withdrawal. The primary symptom assessed was jumping from
an elevated platform (32 cm high, 17 cm diameter). The proportion of mice that jumped from their
individual platforms was recorded over a 10 min trial. The proportion of jumping mice is
considered an index of withdrawal (Fitting et al., 2016). This test was followed by an evaluation
of additional signs of withdrawal. Mice were placed in a rectangular, clear, plastic observation box
(16 × 16 × 30 cm) and observed for 5 min. The concomitant number of jumps, forepaw tremors,
and wet-dog shakes was recorded. The frequency of jumps, tremors, and shakes are considered
additional indices of withdrawal (Fitting et al., 2016).

2.4.3. Conditioned Place Preference
Behavior in the CPP test was recorded and digitally-encoded by an ANY-maze behavioral
tracking system (Stoelting Co., Wood Dale, IL, USA). Morphine-CPP and locomotor sensitization
were assessed simultaneously (Zhu et al., 2015). CPP was conducted as modified from previous
methods (Paris et al., 2014). The apparatus (#64101; Stoelting Co.) consisted of two black
conditioning chambers (18 × 20 × 35 cm), each visually-distinguished by the presence of white
circles or horizontal stripes on the chamber walls, as well as ~30 lux difference in ambient lighting.
Conditioning chambers were connected by a start box/transition chamber (10 × 20 cm). A biased
conditioning design was utilized (Semenova et al., 1995). On day 1, mice were allowed to freely

44

explore the apparatus for 10 min in order to establish an initial chamber-preference (there was no
significant side preference observed across experimental groups). On days 2 – 5 mice underwent
one cycle of morphine conditioning per day (receiving an i.p. saline injection paired with
confinement to the preferred chamber for 30 min, followed 4 h later by an i.p. morphine, 10 mg/kg,
injection paired with confinement to the less preferred chamber for 30 min). Twenty-four hours
after the last morphine-conditioning cycle, mice were allowed to freely explore the apparatus in
order to assess their final chamber preference. The amount of time that mice spent in the chambers
or the start/transition box, as well as the distance traveled, and the frequency of rearing was
recorded on each day. CPP was quantified as a difference score: CPP d-score = (time spent in the
morphine-paired chamber) – (time spent in the saline-paired chamber) (Paris et al., 2014a).
2.4.4. Rotarod
Locomotor coordination was assessed on an accelerated rotarod as previously described
(Paris et al., 2013). Briefly, mice were trained to balance on an immobile rotarod (3 cm in diameter
and suspended 44.5 cm high; Columbus Instruments, Columbus, OH, USA) for 30 sec. Mice were
then trained to navigate the task across two 30 sec fixed speed trials (10 rpm) and two 180 sec
fixed speed trials (10 rpm). Lastly, mice were tested on two accelerated speed trials (180 sec max.
latency at 0 - 20 rpm). The mean latency to fall from the rotarod and the maximum RPM achieved
across the two accelerated trials were utilized as indices for locomotor performance. Decreased
latencies to fall and lower maximal RPM on the accelerated test indicate an impaired motor
phenotype.
2.5. Cytokine assay
The head of the caudate nucleus has been identified as a central reservoir for maximal HIV
viral load in humans (reviewed in Nath, 2015) and we have found the striatum to host a cell
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population that may be selectively vulnerable to HIV-1 Tat (Schier et al., 2017). As such, cytokine
analyses were conducted on caudate/putamen (dorsal striatum) in the present mouse model. Mice
underwent cervical dislocation and bilateral dorsal striata were immediately dissected, flash-frozen
in liquid nitrogen, and stored at - 80°C until assay. At the time of assay, tissues were homogenized
in IP lysis buffer (#87787; Pierce Biotechnology, Rockford, IL, USA) with a protease/phosphatase
inhibitor cocktail (#04693159001; Roche, Mannheim, Germany). Protein concentrations were
determined via bicinchoninic acid (BCA) assay per kit manufacturer instructions (#23224; Pierce
Biotechnology).
Cytokines were assessed using a Bio-Plex Pro™ Mouse Cytokine 23-plex assay kit
(#M60009RDPD; Bio-Rad Laboratories, Inc., Hercules, CA, USA) and analyzed on a Bio-Plex
200 system. Samples were diluted to a concentration of 500 μg/mL. Unknown samples and
standards were incubated with fluorescent, antibody-tagged microspheres and detected via
streptavidin-phycoerythrin-labeled detection antibodies. Cytokine concentrations were calculated
from respective standard curves via Bio-Plex Manager 4.0 software. All samples were analyzed in
duplicate. Limits of detection ranged from 2 to 20 pg/mL. Mean intra- and inter-assay coefficients
of variance were 7.2 % and 5.3 %, respectively.
2.6. Statistical analyses
Median effective doses (ED50; reported with 95 % confidence intervals) were determined
via non-linear regression (sigmoidal curvilinear modeling with variable slope) using a leastsquares fit for each treatment group (bottom and top values constrained to 0 and 100, respectively).
Dependent measures for additional behavioral analyses were assessed via ANOVA (to assess
dependence) or repeated measures ANOVA (to assess psychostimulation or CPP over multiple
trials) with drug condition (placebo or morphine), inhibitor condition (vehicle or maraviroc), and
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genotype [Tat(-) or Tat(+)] as factors. Cytokine arrays were assessed via separate three-way
ANOVAs. Mice treated acutely with doxycycline (48 h) were analyzed with morphine condition
(acute saline or acute morphine), inhibitor condition (vehicle or maraviroc), and genotype [Tat(-)
or Tat(+)] as factors. Mice treated chronically with doxycycline for 28 days were analyzed with
morphine condition (morphine-naïve, repeated morphine, or 24 h post morphine), inhibitor
condition (vehicle or maraviroc), and genotype [Tat(-) or Tat(+)] as factors. Fisher’s Protected
Least Significant Difference post-hoc tests determined group differences following main effects.
Interactions were delineated via simple main effects and main effect contrasts with alpha
controlled for multiple comparisons. Analyses were considered significant when p < 0.05.

3. Results
3.1. HIV-1 Tat decreased morphine potency in non-tolerant mice; tolerance or pharmacological
antagonism of CCR5 attenuated Tat effects
As negative control measures before proceeding to tests involving Tat-transgenic mice,
morphine dosing, non-specific interactions with maraviroc, and warm-water tail withdrawal test
conditions were confirmed in C57BL/6J mice. In a 52°C water bath, morphine administered at 5
mg/kg (Fig. 1A) or 10 mg/kg (Fig. 1B) produced antinociception that was present for at least 2 h
and peaked at 60 min, commensurate with observations in other animal models (Altun et al., 2015;
Williams et al., 2008). In a 56°C water bath, cumulative morphine-dosing produced
antinociception commensurate with what we have previously observed in C57BL/6J mice (Fitting
et al., 2016; Fig. 1C). Maraviroc did not significantly influence the acute time-course (Fig. 1A-B)
or the antinociceptive effects of morphine in C57BL/6J mice [vehicle/morphine ED50 = 2.0 (95%
CI: 0.9 – 4.3), maraviroc/morphine ED50 = 3.0 (95% CI: 2.2 – 4.1)] (Fig. 1C).
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Tat(-) and Tat(+) mice were placed on doxycycline for 28 days to induce Tat expression
(or not). On day 28, mice were implanted with a subcutaneous placebo pellet or morphine pellet
to induce morphine tolerance. From days 28 – 32, mice were administered vehicle or maraviroc
(p.o., QD). On day 33, mice received their last dose of vehicle or maraviroc and were tested 30
min later.
Tat induction, morphine tolerance, and maraviroc pretreatment significantly influenced the
antinociceptive response to acute morphine (Fig. 2A-B). Among nontolerant, placebo-pelleted
mice, Tat exposure produced a modest but significant shift to the right in the antinociceptive
potency of acutely-administered morphine [F(1,48) = 7.97, p < 0.05] [Fig. 2A; Tat(-)ED50 = 4.5
(95% CI: 3.6 - 5.5), Tat(+)ED50 = 6.8 (95% CI: 5.6 - 8.0)]. This effect was obviated by maraviroc
pretreatment [Fig. 2B; Tat(-)ED50 = 6.0 (95% CI: 4.9 - 7.1), Tat(+)ED50 = 5.8 (95% CI: 4.9 - 6.7)].
Morphine tolerance significantly shifted the ED50 for morphine-induced antinociception to the
right in all treatment groups [Fig. 2A-B; ED50 range = 17.8 - 53.8]. Notably, baseline tailwithdrawal latencies were ~0.4 sec greater among morphine-pelleted (2.7 ± 0.1 sec) vs. placebo
pelleted mice (2.3 ± 0.1 sec) [F(1,44) = 10.91, p < 0.05]. Neither Tat induction nor maraviroc
pretreatment influenced baseline tail-withdrawal latencies.

3.2. Among tolerant mice, Tat-exposure decreased primary withdrawal behavior;
pharmacological antagonism of CCR5 attenuated Tat effects
Following testing for antinociception, mice were administered the opioid receptor
antagonist, naloxone, and precipitated withdrawal behaviors were assessed. Tat induction,
morphine tolerance, and maraviroc pretreatment significantly interacted to influence the primary
measure of withdrawal, the proportion of mice that jumped from an elevated platform [F(1,44) =
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6.77, p < 0.05] (Fig. 3A). Unlike other withdrawal-related behaviors assessed, elevated platform
jumping was only observed among previously morphine-tolerant mice (a significant difference
from their placebo-pelleted counterparts [F(1,44) = 122.27, p < 0.05]; Fig. 3A). Among morphinetolerant mice, withdrawal precipitated jumping was significantly attenuated by Tat exposure
[Tat(+) mice significantly differed from Tat(-) controls (p = 0.03)] or maraviroc pretreatment
[maraviroc treated, Tat(-) mice significantly differed from Tat(-) controls (p = 0.005)] (Fig. 3A).
However, combined Tat exposure and maraviroc pretreatment restored withdrawal precipitated
jumping [maraviroc-treated Tat(+) mice significantly differed from maraviroc treated Tat(-) mice
(p = 0.004) or vehicle-treated Tat(+) mice (p = 0.03)] (Fig. 3A).
When observed for additional, simultaneous withdrawal-precipitated behaviors, the
frequency of spontaneous jumping was significantly greater [F(1,44) = 10.83, p < 0.05] (Fig. 3B)
and paw tremors were significantly reduced [F(1,44) = 10.79, p < 0.05] (Fig. 3C) among morphinetolerant mice compared to placebo-pelleted controls, irrespective of Tat or maraviroc exposure.
There was a main effect for wet-dog shakes to be significantly greater among Tat(+) mice
compared to Tat(-) mice, irrespective of morphine or maraviroc exposure [F(1,44) = 3.97, p =
0.05] (Fig. 3D).
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3.3. HIV-1 Tat exposure and CCR5 antagonism attenuated the psychomotor response to
morphine
Both Tat exposure and maraviroc pretreatment interacted with repeated morphine
injections to influence locomotor behavior (Fig. 4AB). Among vehicle-pretreated mice, morphine
administration significantly increased the distance traveled in the CPP apparatus [F(7,147) = 16.66,
p < 0.05] compared to saline administration, irrespective of Tat exposure (p < 0.0001 per day; Fig.
4A). However, among maraviroc-pretreated mice, Tat-exposure and morphine administration
significantly interacted [F(7,147) = 2.46, p < 0.05] such that Tat(-) mice receiving morphine
demonstrated significantly greater distances traveled on days 1 (p = 0.03) and 4 (p = 0.003),
compared to Tat(+) mice receiving morphine (Fig. 4B). Tat(-) mice also displayed enhanced
locomotion to a significantly greater degree following morphine administration than following
saline administration (p < 0.0001 per day); whereas, locomotion among Tat(+) mice did not differ
between morphine or saline administration (Fig. 4B). Notably, Tat exposure can impair locomotion
on its own; however, these effects are not usually observed in the present model until Tat has been
induced for over one month (Hahn et al., 2012). To rule out nonspecific effects of Tat on
locomotion, some Tat(-) and Tat(+) mice from the present experiment were assessed on an
accelerated rotarod after testing. No significant differences in locomotor capacity were observed
following fixed speed trials (10 rpm) lasting 30 s [Tat(-): 9 ± 2, Tat(+): 12 ± 2] or 180 s [Tat(-): 56
± 16, Tat(+): 81 ± 20], or following accelerated speed trials (0 – 20 rpm) lasting 180 s [Tat(-): 132
± 10, Tat(+): 128 ± 14].
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3.4. CCR5 antagonism potentiated Tat-related morphine reward
To assess the contribution of HIV-1 Tat on the rewarding properties of morphine, mice
were assessed for morphine-CPP. Tat(-) and Tat(+) mice were exposed to two morphine
conditioning cycles (saline followed by morphine) and assessed for chamber preference 24 h after
the last morphine administration (Fig. 5A). Following two conditioning cycles, morphine
significantly increased the time that mice spent in the previously non-preferred chamber [F(1,24)
= 26.84, p < 0.05] (Fig. 5A’). However, significant differences between Tat(-)and Tat(+) mice
were not observed (Fig. 5A’).
Another group of mice underwent four morphine-conditioning cycles and were assessed
for final chamber preference 24 h later (Fig. 5B). Under these conditions, Tat genotype
significantly interacted with the final preference trial [F(1,22) = 5.43, p < 0.05] (Fig. 5B’). Tat(-)
and Tat(+) mice spent a commensurate amount of time in the least preferred chamber prior to
conditioning; but, Tat(+) mice spent a significantly greater amount of time in the morphine-paired
chamber following four cycles of morphine conditioning compared to Tat(-) controls (p = 0.04;
Fig. 5B’).
To assess the influence of CCR5 on Tat-potentiated CPP, Tat(-) and Tat(+) mice were
pretreated with vehicle or maraviroc 30 min prior to the start of conditioning over four cycles (Fig.
5C). As previously observed, mice significantly preferred the morphine paired chamber 24 h
following conditioning, irrespective of treatment [F(1,42) = 100.80, p < 0.05] (Fig. 5C’). There
was significant interaction between Tat-genotype and maraviroc condition [F(1,42) = 4.13, p <
0.05], such that Tat(+) mice spent a significantly greater amount of time in the morphine-paired
chamber when pretreated with maraviroc than did any other group (p = 0.0006 – 0.02; Fig. 5C’).
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3.5. Prior morphine exposure and HIV-1 Tat increase striatal cytokine content and CCR5
antagonism attenuates Tat effects
Cytokine protein expression was assessed in the dorsal striatum (caudate/putamen) of Tat
(-) and Tat(+) mice. In order to parse the acute- vs. chronic influences of Tat, maraviroc, and
morphine on the immune effectors examined, tissues from two separate groups of mice were
assessed. The first group was acutely exposed to Tat (48 h of doxycycline to induce Tat), maraviroc
(a single administration of vehicle or maraviroc, 62 mg/kg, p.o., 30 min prior to i.p. injection), and
morphine (a single administration of saline or morphine, 10 mg/kg, i.p.). The second group was
chronically exposed to Tat (28 d of doxycycline to induce Tat), repeated maraviroc (vehicle or
maraviroc, 62 mg/kg, p.o., QD for 4 d, 30 min prior to i.p. injection), and repeated morphine (saline
or morphine, 10 mg/kg, i.p., QD for 4 d). Tissues were collected either
1 h after the last treatment, or 24 h after the last treatment (the latter timeframe being commensurate
with that which produced Tat-potentiated morphine-CPP).

3.5.1. Chemotactic Cytokines
Among mice that were acutely-exposed to Tat and drug manipulations (Fig. 6, left-hand
panels, 48 h doxycycline exposure), acute Tat induction and acute maraviroc pretreatment
significantly interacted to increase striatal CCL3, compared to vehicle treated, Tat(-) controls
[F(1,31) = 4.69, p < 0.05] (Fig. 6B, left panel, white bars). There was an additional interaction for
acute morphine to significantly increase CCL5, but only among Tat(+) mice [F(1,31) = 4.59, p <
0.05] (Fig. 6G, left panel, cyan bars). Main effects were observed for acute Tat exposure to
significantly increase CCL4 [F(1,31) = 15.56, p< 0.05] (Fig. 6C, left panel, white and cyan bars)
and CCL11 [F(1,31) = 5.56, p < 0.05] (Fig. 6H, left panel, white and cyan bars), irrespective of
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maraviroc or morphine administration. Lastly, there was a main effect for morphine to significantly
elevate CXCL1 [F(1,31) = 10.55, p < 0.05], irrespective of Tat or maraviroc exposure (Fig. 6D,
left panel, cyan bars). Acute treatments did not otherwise influence the chemokines examined.
Among mice exposed to chronic Tat and repeated morphine, no significant differences
were observed until morphine was withheld for 24 h (Fig. 6, right-hand panels, 28 d doxycycline
exposure). Three-way interactions were revealed 24 h post morphine treatment for CCL2 [F(2,45)
= 3.64, p < 0.05] (Fig. 6A, right panel, gray bars), CCL3 [F(2,45) = 6.14, p < 0.05] (Fig. 6B, right
panel, gray bars), CCL4 [F(2,45) = 4.55, p < 0.05] (Fig. 6C, right panel, gray bars), CXCL1
[F(2,45) = 4.21, p < 0.05] (Fig. 6D, right panel, gray bars), G-CSF [F(2,45) = 5.42, p < 0.05] (Fig.
6E, right panel, gray bars), and GMCSF [F(2,45) = 6.11, p < 0.05] (Fig. 6F, right panel, gray bars).
In each case, chronic Tat significantly potentiated the increase of chemokines and maraviroc
pretreatment significantly ameliorated this potentiation (see outlined chemokines in Fig. 6).
Additionally, a main effect was observed for CCL5 to be increased 24 h post morphine
administration, irrespective of Tat or maraviroc exposure [F(2,45) = 115.48, p < 0.05] (Fig. 6G,
right panel, gray bars). Intriguingly, repeated morphine significantly reduced CCL11 [F(2,45) =
3.25, p < 0.05], an effect that was prevented by maraviroc pretreatment (Fig. 6H, right panel,
magenta bars). Once morphine was withheld for 24 h, CCL11 declined in all groups (Fig. 6H, right
panel, gray bars).

3.5.2. Pro-inflammatory cytokines
Acute HIV-1 Tat and maraviroc/morphine exposure (Fig. 7, left-hand panels, 48 h
doxycycline exposure) influenced pro-inflammatory cytokine levels. A significant interaction was
observed for acute morphine to modestly elevate IL-1α, but only in maraviroc-pretreated mice
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[F(1,31) = 6.11, p < 0.05] (Fig. 7G, left panel, cyan bars). Acute Tat also significantly increased
IL-3 (which was attenuated by maraviroc) [F(1,31) = 3.82, p = 0.05] (Fig. 7A, left panel, white
bars) and IL-9 (which was attenuated by morphine and reinstated by maraviroc) [F(1,31) = 3.96,
p = 0.05] (Fig. 7C, left panel, white and cyan bars). Lastly, there was a main effect for acute Tat
exposure to cause a modest, significant increase in IL-1α [F(1,31) = 7.03, p < 0.05] (Fig. 7G, left
panel, white and cyan bars) and a main effect for acute maraviroc to increase IL-6 [F(1,31) = 4.07,
p < 0.05] (Fig. 7B, left panel, white bars). No additional effects of acute treatments were observed
on pro-inflammatory cytokines.
In mice exposed to chronic Tat and repeated maraviroc/morphine treatment, significant
elevations were observed in all pro-inflammatory cytokines examined (Fig. 7, right-hand panels,
28 d doxycycline exposure). Three-way interactions were revealed 24h post morphine treatment
for IL-3 [F(2,45) = 6.73, p < 0.05] (Fig. 7A, right panel, gray bars), IL-6 [F(2,45) = 3.14, p = 0.05]
(Fig. 7B, right panel, gray bars), IL-9 [F(2,45) = 5.18, p < 0.05] (Fig. 7C, right panel, gray bars),
IL-12p40 [F(2,45) = 4.02, p < 0.05] (Fig. 7D, right panel, gray bars), IL-12p70 [F(2,45) = 5.43, p
< 0.05] (Fig. 7E, right panel, gray bars), and IL-17A [F(2,45) = 5.65, p < 0.05] (Fig. 7F, right
panel, gray bars). In each case, chronic Tat significantly potentiated the increase of
proinflammatory cytokines and maraviroc pretreatment significantly ameliorated this potentiation
(see outlined cytokines in Fig. 7). A 3-way interaction was also revealed for IFN-γ to be
significantly increased among mice that were exposed to chronic Tat and repeated
maraviroc/morphine [F(2,45) = 3.23, p < 0.05] (Fig, 7J, right panel, magenta bars). These effects
were significantly exacerbated 24 h post morphine; however, this potentiation was not significantly
attenuated by maraviroc-pretreatment (Fig, 7J, right panel, gray bars). Interestingly, repeated
morphine also significantly increased IL-9 content in maraviroc-pretreated mice [F(2,45) = 5.63,
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p < 0.05] (Fig. 7C, right panel, magenta bars). Irrespective of Tat and maraviroc exposure, main
effects were observed for cytokines to be increased 24 h post morphine for IL-1α [F(2,45) = 80.55,
p < 0.05] (Fig. 7G, right panel, gray bars), IL-1β [F(2,45) = 288.09, p < 0.05] (Fig. 7H, right panel,
gray bars), IL-2 [F(2,45) = 475.92, p <0.05] (Fig. 7I, right panel, gray bars), and TNF-α [F(2,45)
= 42.36, p < 0.05] (Fig. 7K, right panel, gray bars).
3.5.3. Anti-inflammatory cytokines
Among the anti-inflammatory cytokines assessed, only IL-10 demonstrated a significant
response to acute manipulations (Fig. 8, left-hand panels, 48 h doxycycline exposure), [F(1,31) =
5.56, p < 0.05]. Acute Tat exposure significantly increased IL-10, and this effect was attenuated
by maraviroc unless co-administered with acute morphine (Fig. 8A, left panel, white and cyan
bars).
When assessed for chronic Tat exposure and repeated maraviroc/morphine administration
(Fig. 8, right-hand panels, 28 d doxycycline exposure), IL-10 was the only anti-inflammatory
cytokine that demonstrated Tat-mediated potentiation 24 h post morphine that was reversible by
pretreatment with maraviroc [F(2,45) = 6.46, p < 0.05] (Fig. 8A, right panel, gray bars). Other
anti-inflammatory cytokines demonstrated significant main effects for enhanced protein
expression 24 h post morphine, but not in a Tat- or maraviroc-sensitive manner: IL-4 [F(1,45) =
499.77, p < 0.05] (Fig. 8B, right panel, gray bars), IL-5 [F(2,45) = 3.45, p < 0.05] ] (Fig. 8C, right
panel, gray bars), and IL-13 [F(2,45) = 313.62, p < 0.05] ] (Fig. 8D, right panel, gray bars).
Additionally, a main effect for 28 d Tat exposure to significantly increase IL-4 was observed
[F(1,45) = 9.13, p < 0.05], independent of maraviroc or morphine administration (Fig. 8B, right
panel, yellow/magenta/gray bars).
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Figure 1: Maraviroc did not significantly influence the antinociceptive response to morphine
in C57BL/6J mice. Latency to tail withdrawal (% MPE ± SEM) among C57BL/6J mice (n = 5 /
group) that were administered vehicle (p.o.; black circles) or maraviroc (62 mg/kg, p.o.; blue
circles) prior to (A) morphine (5 mg/kg, s.c.), (B) morphine (10 mg/kg, s.c.), or (C) a cumulative
morphine dosing regimen (2 – 16 mg/kg, s.c.).
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Figure 2: HIV-1 Tat significantly shifted the ED50 for morphine to the right in nontolerant
mice and maraviroc pretreatment obviated this effect. Latency to tail withdrawal (% MPE ±
SEM) among Tat(-) or Tat(+) mice (n = 6 - 7 / group) that were morphine-naïve (placebo-pelleted;
circles) or morphine-tolerant (morphine-pelleted; triangles). Mice [Tat(-) in black, Tat(+) in red]
were administered (A) daily vehicle (p.o.) or (B) daily maraviroc (62 mg/kg, p.o.) following
pelleting and were assessed for tail withdrawal reflex in response to a cumulative morphine
regimen (2 - 64 mg/kg, s.c.). * indicates a significant shift in ED50, p < 0.05.
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Figure 3: HIV-1 Tat significantly attenuated withdrawal-precipitated jumping and
maraviroc pretreatment reversed this effect; Tat and morphine tolerance influenced
additional withdrawal symptomology. Measures of naloxone-precipitated withdrawal among
Tat(-) or Tat(+) mice [n = 6 - 7 / group; Tat(-) in open bars, Tat(+) in hatched bars] that were
morphine-naïve (placebo-pelleted; left bars in each panel) or morphine-tolerant (morphinepelleted; right bars in each panel), administered daily vehicle (p.o.; white bars) or maraviroc (62
mg/kg, p.o.; black bars), and assessed for warm water tail withdrawal. (A) The proportion of mice
jumping from an elevated platform over 10 min, as well as the concomitant frequency of (B)
spontaneous jumping, (C) paw tremor, and (D) wet dog shakes over 5 min in an observation box,
were recorded. * main effect of Tat-exposure [greater wet-dog shakes among Tat(+) mice vs. Tat(-
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) mice]. † main effect of prior morphine tolerance (greater frequency of spontaneous jumps and
fewer simultaneous paw tremors among morphine-tolerant vs. non-tolerant mice). ‡ interaction for
indicated groups to differ from morphine-tolerant Tat(-) mice or morphine-tolerant, maraviroc
treated Tat(+) mice, p < 0.05.

Figure 4:

HIV-1 Tat and maraviroc significantly attenuate morphine-mediated

psychomotor behavior. Locomotor behavior in response to saline (i.p. for 4 days; open circles)
morphine (10 mg/kg, i.p. for 4 days; closed circles) was assessed during conditioning cycles among
Tat(-) or Tat(+) mice that were pretreated with (A) vehicle (p.o.) or (B) maraviroc (62 mg/kg, p.o.;
n = 11 - 12 / group). † main effect of morphine (greater locomotion following morphine vs. saline
treatment). ‡ interaction for indicated Tat(-) groups differ from their respective Tat(+)
counterparts, p < 0.05.
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Figure 5: HIV-1 Tat potentiates morphine-conditioned place preference 24 h post morphine
and maraviroc pretreatment exacerbates this effect. Tat(-) or Tat(+) mice (n = 11 - 14 / group)
were assessed for their chamber preference (open circles) in a biased conditioned place preference
(CPP) test consisting of either (A) two cycles of saline (i.p.)/morphine (10 mg/kg, i.p.)
conditioning (closed squares), (B) four cycles of saline/morphine conditioning (closed squares),
or (C) four cycles of vehicle (p.o.) or maraviroc pretreatment (gray triangles) followed by
saline/morphine conditioning (closed squares). Initial preferences for the morphine-paired
chamber (left of dashed line) are depicted followed by final CPP (right of dashed line) after (A’)
two conditioning cycles, (B’) four conditioning cycles, or (C’) vehicle/maraviroc pretreatment
prior to four conditioning cycles. Tat(-) mice are depicted in open bars, Tat(+) mice are depicted
in hatched bars, vehicle (p.o.)-pretreated mice are depicted with white bars, and maraviroc (62
mg/kg, p.o.)-pretreated mice are depicted with black bars. † main effect for the final chamber
preference to differ from the initial preference. * interaction for Tat(-) mice to differ from Tat(+)
mice. ‡ interaction for maraviroc-pretreated Tat(+) mice to differ from all other groups, p < 0.05.
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Figure 6: Chemokine expression in caudate/putamen is largely upregulated 24 h following
repeated morphine exposure; HIV-1 Tat potentiated this effect on some analytes (outlined)
which was ameliorated by maraviroc pretreatment. Chemotactic cytokine protein expression
(pg/mL ± SEM) in dorsal striatum (caudate/putamen) of vehicle- (p.o.) or maraviroc- (62 mg/kg,
p.o.) exposed mice [n = 4 – 5 / group; Tat(-) in open bars, Tat(+) in stippled bars] that had Tat
expressed for 48 h or 28 days (via doxycycline). Mice were administered saline (i.p.; white bars)
or morphine (10 mg/kg, i.p., QD) acutely (cyan bars), repeatedly (4 consecutive days; repeated
saline in yellow bars and repeated morphine in magenta bars), or were 24 h post repeated morphine
treatment (gray bars). Cytokines within the dashed box demonstrated Tat-potentiation that was
ameliorated by maraviroc. @ main effect of Tat [Tat(+) mice have greater expression than Tat(-)
mice, irrespective of morphine or maraviroc condition]. † main effect of morphine (indicated
morphine group has greater expression than the respective saline group, irrespective of Tat or
maraviroc condition). || maraviroc-morphine interaction (indicated maraviroc-treated group differs
from vehicle-treated control within the same morphine condition). * 3-way interaction for
indicated groups to differ from vehicle-treated, saline administered, Tat(-) controls. ‡ 3-way
interaction for indicated group to differ from all other groups. § 3-way interaction for indicated
groups to differ from respective vehicle treated, Tat(-) control within the 24 h post morphine group.
^ 3-way interaction for indicated maraviroc-treated Tat(+) group be reduced compared to
respective vehicle treated Tat(+) group, p < 0.05.
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Figure 7: Proinflammatory cytokine expression in caudate/putamen is partly upregulated 24
h following repeated morphine exposure; HIV-1 Tat potentiated this effect on some analytes
(outlined) which could be ameliorated by maraviroc pretreatment. Proinflammatory cytokine
protein expression (pg/mL ± SEM) in dorsal striatum (caudate/putamen) of vehicle- (p.o.) or
maraviroc- (62 mg/kg, p.o.) exposed mice [n = 4 – 5 / group; Tat(-) in open bars, Tat(+) in stippled
bars] that had Tat expressed for 48 h or 28 days (via doxycycline). Mice were administered saline
(i.p.; white bars) or morphine (10 mg/kg, i.p., QD) acutely (cyan bars), repeatedly (4 consecutive
days; repeated saline in yellow bars and repeated morphine in magenta bars), or were 24 h post
repeated morphine treatment (gray bars). Cytokines within the dashed box demonstrated Tatpotentiation that was ameliorated by maraviroc. @ main effect of Tat [Tat(+) mice have greater
expression than Tat(-) mice, irrespective of morphine or maraviroc condition]. † main effect of
morphine (indicated morphine group has greater expression than the respective saline group,
irrespective of Tat or maraviroc condition). ζ main effect of maraviroc (maraviroc-treated groups
have significantly greater expression that vehicle-treated groups, irrespective of Tat or morphine
condition). ## Tat-morphine interaction wherein Tat(-) and Tat(+) mice in the indicated morphine
group are greater than those in other morphine groups and differ from each other (irrespective of
maraviroc condition). || maraviroc-morphine interaction wherein maraviroc-pretreatment differs
from vehicle-pretreatment within the indicated morphine groups (irrespective of Tat condition). *
3-way interaction for indicated groups to differ from respective vehicle-treated, saline
administered, Tat(-) controls. ‡ 3-way interaction for indicated group to differ from all other
groups. § 3-way interaction for indicated groups to differ from respective vehicle treated, Tat(-)
control within the 24 h post morphine group. ^ 3-way interaction for indicated group to differ from
respective vehicle-treated, acute-saline-administered, Tat(+) mice. + 3-way interaction for
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indicated group to be greater than their maraviroc treated, Tat(-) counterparts within the 24 h post
morphine group, p < 0.05.
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Figure 8: Anti-inflammatory cytokine expression in caudate/putamen is upregulated 24 h
following repeated morphine exposure; HIV-1 Tat potentiated this effect on IL-10 and
maraviroc pretreatment ameliorated this effect. Anti-inflammatory cytokine protein expression
(pg/mL ± SEM) in dorsal striatum (caudate/putamen) of vehicle- (p.o.) or maraviroc- (62 mg/kg,
p.o.) exposed mice [n = 4 – 5 / group; Tat(-) in open bars, Tat(+) in stippled bars] that had Tat
expressed for 48 h or 28 days (via doxycycline). Mice were administered saline (i.p.; white bars)
or morphine (10 mg/kg, i.p., QD) acutely (cyan bars), repeatedly (4 consecutive days; repeated
saline in yellow bars and repeated morphine in magenta bars), or were 24 h post repeated morphine
treatment (gray bars). The dashed box indicates IL-10 as the only anti-inflammatory cytokine
assessed that demonstrated Tat-potentiation with maraviroc amelioration. @ main effect of Tat
[Tat(+) mice have greater expression than Tat(-) mice, irrespective of morphine or maraviroc
condition]. † main effect of morphine (indicated morphine group has greater expression than the
respective saline group, irrespective of Tat or maraviroc condition). * 3-way interaction for
indicated groups to differ from vehicle-treated, saline-administered, Tat(-) controls. ‡ 3-way
interaction for indicated group to differ from all other groups. § 3- way interaction for indicated
groups to differ from respective vehicle-treated, Tat(-) control within the 24 h post morphine
group. ^ 3-way interaction for indicated group be reduced compared to respective vehicle-treated
Tat(+) group, p < 0.05.
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Figure 9: Proposed mechanism(s) of morphine/maraviroc interaction with or without HIV1 Tat-induced neuroinflammation. (A) In the absence of Tat-mediated neuroinflammation [as
modeled using (Tat-), control mice], morphine is behaviorally efficacious, partly via actions at mu
opioid receptor (MOR) oligomers or MOR-CCR5 heteromers. MOR signaling may crossdesensitize CCR5 oligomers in this state (not depicted). (B) When no prior neuroinflammatory
stimulus is present, the addition of maraviroc exerts little influence on the behavioral efficacy of
morphine [as modeled using (Tat-), maraviroc-treated mice]. (C) When Tat-induced
neuroinflammation is present [as modeled using Tat(+) mice], there are enhanced levels of βchemokines that bind CCR5 and may cross-desensitize MORs. When morphine is administered in
this state, its behavioral efficacy is attenuated. (D) The addition of maraviroc when
neuroinflammation is present may block the ability of CCR5 to cross-desensitize MORs, thereby
restoring morphine efficacy [as modeled using maraviroc-treated, Tat(+) mice].
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4. Discussion
The overall hypotheses that HIV-1 Tat expression attenuates morphine potency, CCR5
antagonism reverses these effects, and withholding morphine for 24 h exacerbates Tat’s effects on
cytokines were upheld. The present data revealed even greater nuance in the behavioral response
to morphine regimens than was anticipated. Consistent with prior reports (Fitting et al., 2012,
2016), HIV-1 Tat expression significantly attenuated the antinociceptive potency of acute
morphine injection (2 – 64 mg/kg, i.p.) and significantly attenuated aspects of withdrawal among
mice made tolerant via subcutaneous implant of a morphine pellet (75 mg). The present work
further extends these findings to demonstrate that pretreatment with the CCR5 antagonist,
maraviroc, blocks the effects of Tat on morphine tolerance and dependence behaviors (reinstating
morphine potency in non-tolerant mice and restoring aspects of withdrawal symptomology in
morphine tolerant mice). We further assessed the potential interactions of HIV-1 Tat and
maraviroc on morphine reward via a CPP assay. Tat reduced the locomotor response associated
with repeated, once-daily, morphine injections (10 mg/kg. i.p.) over 4 days of conditioning, but
significantly potentiated (~3.5-fold) morphine-CPP after morphine was withheld for 24h. These
results are congruent with prior findings of Tat-potentiated psychostimulant and ethanol reward
(McLaughlin et al., 2014; Mediouni et al., 2015; Paris et al., 2014a,b) and a slower rate of
extinction in HIV-1 transgenic rats contextually conditioned to morphine (Homji et al., 2012).
Surprisingly, maraviroc further potentiated Tat’s effects on morphine mediated locomotion and
CPP (~5.7-fold), but exerted no influence on these behaviors when administered alone. Protein
arrays revealed that withholding morphine for 24 h (commensurate with the timeframe of CPP
assessment) markedly increased the levels of multiple categories of cytokines (proinflammatory,
anti-inflammatory, and regulatory), suggesting a widespread dysregulation of immune function.
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Importantly, maraviroc could block or attenuate the immunological consequences of terminating
morphine administration across a number of cytokines. Tat-dependent elevations in the
endogenous CCR5 ligands (CCL3 and CCL4) and CCL2 (whose activation is proposed to be
downstream of CCR5-dependent Tat/opioid interactions; El-Hage et al., 2008), as well as other
cytokines increased by Tat, were markedly attenuated by maraviroc.
The marked increase in a large number of cytokines that was observed 24 h after
withholding repeated morphine (10 mg/kg/d) was unanticipated and may be contributed to by
several sources. Although immune function is generally suppressed by sustained opioid exposure
(Bayer et al., 1994; Rahim et al., 2003), it can transiently rebound followed by sustained
immunosuppression after opioid withdrawal (Eisenstein et al., 2006; Rahim et al., 2004).
Contextual cues alone (such as those used in CPP) alter immune responding once opiate
conditioning is established (Hutson et al., 2017; Saurer et al., 2011), effects that involve the ventral
striatum (Szczytkowski et al., 2011). Alternatively, chronic doxycycline treatment can produce
alterations in the gut microbiome (Angelakis et al., 2014) which may influence immune responding
and subsequent behavior. Interestingly, in this study we found that chronic doxycycline treatment
upregulated some but not all chemokines and cytokines in dorsal striatum of both Tat(−) and Tat(+)
mice (CCL5, IL-1α, IL-1β, IL-2, IL-6, and IL-13 were upregulated in chronic, compared to acute,
doxycycline exposure). There is increasing evidence that microbial dysbiosis can influence many
centrally mediated effects, including anxiety and mood (Cryan and Dinan, 2012; Foster et al.,
2013). We have previously reported that HIV-1 Tat can induce bacterial translocation and enhance
pro-inflammatory cytokines via TLR4 activation in the mouse colon (Guedia et al., 2016). Chronic
morphine has also been reported to induce microbial dysbiosis and increase pro-inflammatory
cytokines within the gut (Kang et al., 2017; Meng et al., 2013). In particular, morphine pellets have
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been observed to induce sepsis (Eisenstein et al., 2006; Feng et al., 2005; Hilburger et al., 1997)
which may be due, in part, to intestinal stasis. Given that HIV-1 Tat has been shown to increase
the permeability of the blood-brain barrier (Leibrand et al., 2017), the presence of Tat may
compound the central accumulation of systemic factors including cytokines. The present findings
support previous literature demonstrating MOR and CCR5 interactions on HIV-1 Tat-mediated
cellular outcomes and begin to reveal the related behavioral sequelae.
The comorbidity between opioid abuse and HIV is well established. The cellular/molecular
interactions between opioids and HIV co-receptors are less well understood, but may exert
important effects on chemokine function. Opioids modulate CCR5 expression and signaling in
vitro. Morphine or methadone upregulates CCR5 mRNA and protein expression in murine BV-2
derived microglia (Bokhari et al., 2009). human astrocytes (Mahajan et al., 2005b), human
lymphoid cell lines (Miyagi et al., 2000; Suzuki et al., 2002), or human monocyte-derived
macrophages (Guo et al., 2002; Li et al., 2003) or microglia (Guo et al., 2002). These effects are
functional and confer susceptibility to simian immunodeficiency virus (SIV; (Miyagi et al., 2000;
Suzuki et al., 2002a,b)) or R5-tropic HIV (Guo et al., 2002; Li et al., 2003). Importantly, CCR5
upregulation and viremia has been shown to be attenuated with opioid receptor antagonists, such
as naltrexone (Guo et al., 2002), naloxone (Mahajan et al., 2005b), or the quaternary opioid
antagonist, methylnaltrexone (Ho et al., 2003). These effects are, at least partly, dependent on
actions at MORs given that the highly selective MOR agonist, DAMGO, upregulates CCR5 and
enhances R5-HIV viremia in vitro, an effect that is blocked by the MOR-selective antagonist,
CTAP (Steele et al., 2003). In addition to altered CCR5 expression, MOR and CCR5 undergo
heterologous cross-desensitization (Szabo et al., 2003, 2002; Zhang et al., 2004), which may occur
through convergent signaling or via direct molecular interactions involving the formation of MOR-
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CCR5 heteromers. Evidence for direct MOR-CCR5 dimeric/oligomeric interactions are partly
based on findings that a bivalent ligand comprised naltrexone and maraviroc can reduce the
infectivity of cultured human astrocytes (El-Hage et al., 2013; Yuan et al., 2013) and attenuate R5
HIV-mediated increases in CCL5, TNF-α, and IL-6 in human astrocytes (El-Hage et al., 2013).
Divergent effects of the bivalent ligand were observed in cultured human microglia, which were
much more dynamic in their response to morphine. Unlike astrocytes, microglia demonstrated a
strong upregulation of CCR5 in response to the bivalent ligand in culture that may have accounted
for the differential response between cell types (El-Hage et al., 2013). In other studies, treating a
human lymphoid cell line with morphine and CCL4 (respective agonists for MOR and CCR5)
increased morphine mediated upregulation of CCR5 protein expression (Suzuki et al., 2002c).
Together, our data agree with prior findings (Szabo et al., 2003, 2002; Zhang et al., 2004)
supporting the notion that opioids interact with CCR5 at multiple levels, from the regulation of
CCR5 expression and signaling to potential actions at MOR-CCR5 heteromers and functional
effects on viremia and neuroinflammation. These present findings begin to extend these data to
behavioral dysfunction in a whole-animal model.
Actions at CCR5 may represent a critical point of convergence between the viral protein,
Tat, and MORs. Apart from its role in HIV entry, CCR5 signaling is essential in macrophage and
microglial chemoattraction, the homing of CD8+ T cells, and the pathogenesis of CNS
inflammatory diseases (Martin-Blondel et al., 2016). Foremost, Tat/opioid interactions for
neurotoxicity appear to be dependent on glial MORs. While Tat demonstrates neurotoxicity in cocultured neurons from either wildtype mice or MOR knockout mice, these effects are potentiated
by pretreatment with morphine only when neurons are co-cultured with wildtype glia (MORknockout glia do not potentiate toxicity; Zou et al., 2011). Second, Tat/opioid toxicity largely
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involves downstream neuroinflammation. In murine progenitors, Tat and opioids have interactive
effects on astroglial chemokine secretion (Hahn et al., 2010), CCL5 is often the predominant
central chemokine upregulated in response to Tat, an effect that can be potentiated by chronic
morphine (Dutta and Roy, 2015) and inactivating CCR5 with an antibody blocks the
chemoattractive effects promoted by Tat (Hahn et al., 2010). Third, CCL5 activation appears to
work in concert with downstream chemokine activation, particularly CCL2. In support, morphine
stimulates production of CCL5 and CCL2 in cultured peripheral blood mononuclear cells (Wetzel
et al., 2000) and Tat increases CCL2 and CCL5 production in murine primary astrocyte cultures;
effects that are potentiated by co-application of morphine and reversed by MOR antagonists (such
as β-FNA; El-Hage et al., 2005). Striatal infusion of Tat1-86 to mice significantly increases the
proportion of CCL5 immunoreactive astroglia and co-administration of morphine and Tat
significantly increases astrogliosis, microgliosis, the proportion of CCL2 immunofluorescent
astrocytes/macrophages/microglia, and reactive nitrosative species co-localized to these cells (ElHage et al., 2008a). These effects on murine striatum are obviated by CCL5 knockout (El-Hage et
al., 2008a) or knockout of the CCL2 receptor (El-Hage et al., 2006). Findings in primary human
astrocytes are supportive with morphine downregulating CCL2 and CCL4 mRNA and
upregulating their receptors in a naloxone-dependent manner (Mahajan et al., 2005b). Thus, Tat
and opioids acting at MORs appear to activate CCR5 and CCR2 signaling, increasing
neuroinflammation and striatal neurotoxicity. These effects may contribute to the attenuated
therapeutic efficacy and increased rewarding properties of morphine that we have observed herein.
We propose that MOR-CCR5 cross-desensitization may contribute to the behavioral
pathology observed (Fig. 9). When HIV-1 Tat-mediated neuroinflammation was not present [as
modeled using Tat(-) control mice], cytokine concentrations were at basal levels and morphine
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exerted efficacious effects for tolerance, dependence, psychostimulation, and reward, presumably
via actions partly mediated by MORs (Fig. 9A). The addition of maraviroc to Tat(-) mice did not
influence morphine efficacy on these behavioral measures (Fig. 9B) consistent with in vitro reports
wherein MOR-CCR5 bivalent ligands exert little influence when neuroinflammation is not present
(Akgün et al., 2015; Portoghese et al., 2017). However, when a neuroinflammatory insult was first
present [as modeled using Tat(+) mice], morphine efficacy was diminished on most measures;
perhaps, due to endogenous MORs having already been cross-desensitized by activated CCR5
receptors (Fig. 9C). When maraviroc was introduced in the Tat inflamed state, morphine efficacy
was restored on most measures and even potentiated on the measure of reward. We speculate that
the addition of maraviroc in this state may relieve cross-desensitization, restoring morphine
signaling through its endogenous receptors (Fig. 9D). In support, a bivalent ligand (MOR
agonist/CCR5 antagonist) exerted a 3100-fold increase in potency when administered to LPSinflamed mice, relative to noninflamed controls (Akgün et al., 2015; Portoghese et al., 2017).
There was one behavioral exception to Tat’s capacity to attenuate morphine efficacy and that was
on the measure of reward prior to maraviroc. These divergent findings may involve the role of
additional brain regions and opioid signaling beyond that involving CCR5 heterodimers
(Shippenberg et al., 2009).
It must be noted that the timing of morphine and Tat-dependent interactions at CCR5 is
likely to be critical in determining the nature of the outcome (see Fig. 9 in (Berman et al., 2006;
Song et al., 2011)). The relative increases in cytokines seen with acute morphine and/or Tat
exposure (for example, as in CCL3, CCL4, CCL5, CXCL1, IL-1α, IL- 9, and IL-10) were often
smaller effects that may either be less biologically significant or may display peak activity earlier
than the time examined. These effects were largely absent after sustained exposure suggesting that
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the CNS adapts to sustained opiate or HIV-1 Tat insults via mechanisms involving drug tolerance
(Eisenstein et al., 2006) or innate immune tolerance (Biswas SK, 2009; Cavaillon and AdibConquy, 2006), respectively. Future investigations should additionally assess the presence of
endotoxemia which may contribute to these effects (Eisenstein et al., 2006), but may be masked
by downregulation of the innate response.
The present work raises several clinical considerations. Seropositive patients within the
first 100 d of HIV infection demonstrate positive correlations between circulating CCL2, CCL11,
GM-CSF, IL-1α, IL-6, and lateral ventricular volume as well as IL-5, IL-10, and mean diffusivity
within the caudate (Ragin et al., 2015). Herein, maraviroc exerted little influence over behavioral
measures on its own, but attenuated the capacity for HIV-1 Tat to dampen morphine potency.
Given that up to 40% of HIV-afflicted individuals experience distal polyneuropathies, headache,
and additional chronic pain states (Keswani et al., 2002; Mirsattari et al., 1999) necessitating
opioid medications for relief among a sizeable percentage (~23% of a 1400+ patient sample
infected with HIV; Merlin et al., 2016), maraviroc may have potential benefits to improve opioidbased therapies. However, with chronic opioid use, the beneficial effects of maraviroc are less
clear given that maraviroc was also associated with an increase in withdrawal symptomology and
increased morphine reward. In addition, the neurotoxic actions of additional HIV proteins in the
patient population, such as the HIV coat protein (gp120), may exert a divergent profile compared
to that observed when HIV-1 Tat is expressed alone (Campbell et al., 2015; Maung et al., 2012;
Mocchetti et al., 2013). The toxic effects of R5-tropic gp120 can be attenuated by morphinemediated CCL5 upregulation, perhaps influenced by out-competition for CCR5 (Avdoshina et al.,
2010). As such, future investigations may wish to target MOR-CCR5 bivalent strategies within
the context of opioid dependency across a range of neuroAIDS models.
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5. Conclusions
Several investigations using murine and human cell cultures have demonstrated neurotoxic
interactions between the HIV-1 Tat, MORs, and CCR5. The present findings extend these data by
investigating functional consequences of such interactions on morphine-mediated antinociception,
tolerance, and reward in a murine model. Maraviroc blocked Tat’s actions to attenuate the
antinociceptive potency of acute morphine in nontolerant mice. Intriguingly, maraviroc also
potentiated the Tat-induced increase of morphine-CPP, even while it reduced the levels of many
inflammatory chemokines and cytokines in the striatum including β-chemokines. Thus, while
maraviroc is widely appreciated for its role in blocking HIV entry, it may be considered for
additional therapeutic roles related to pain control in HIV-infected patients; albeit, caution may be
warranted for individuals that are opioid-dependent or at risk for such abuse.
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CHAPTER 4
GAP JUNCTION INHIBITOR CARBENOXOLONE ATTENUATES THE
DEVELOPMENT OF OPIOID ANTINOCICEPTIVE TOLERANCE

1. Introduction
In the clinic, the use of opioids is common for the management of acute and chronic pain.
However, the development of tolerance to the analgesic effects of opioids, such as morphine, leads
to the increase of drug needed to maintain analgesia. Increasing the dose of drug can lead to a
greater chance of unwanted side effects. Tolerance to different effects of opioids occur at different
rates, leading to increased risk of side effects and overdose (Hill et al., 2016; White and Irvine,
1999). Understanding the molecular and cellular mechanisms responsible for this phenomenon
will lead to fewer deaths and potential new analgesics that do not lead to tolerance. A recent target
of interest in understanding the development of tolerance is the gap junction.
Gap junctions are the channel-forming structures between the membranes of two adjoining
cells. Gap junctions allow direct electrical communication between cells, hence they are also
referred to as electrical synapses. Gap junction channels are formed by two hemichannels or
connexons, one contributed by each cell at the synapse (Mccracken and Roberts, 2006; Söhl et al.,
2005). Single hemichannels can exist on the cell membrane providing a pathway for exchange of
intracellular components (including ions and ATP) with the extracellular solution. Such a role has
been proposed for a specific type of gap junction called connexin 43 (Cx43). Its opening results in
the release of glutamate and ATP from astrocytes, which has a major impact on glial-glial and
glial-neuronal interactions. For example, gap junctions found only on neurons as well as only on
glial cells have been found to affect the firing rate of neurons (Blenkinsop and Lang, 2006;
Pannasch et al., 2011).
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It has been suggested that gap junctions participate in particular mechanisms of the pain
pathway. Researchers found that local administration of gap junction inhibitors into the dorsal horn
blocked the inflammation-induced central pain sensitization without changing the baseline pain
responses (Chiang et al., 2010). Recently, researchers have shown that blocking gap junctions
intrathecally attenuated the development of morphine antinociceptive tolerance (Shen et al., 2014).
Gap junctions may play a role in other chronic morphine related effects as well. It has been
observed that the intracerebroventricular administration of the gap junction blocker,
carbenoxolone significantly decreased naloxone-precipitated morphine withdrawal signs (Moradi
et al., 2013). Systemic carbenoxolone blocked morphine-related colonic inflammation and
constipation when administered intraperitoneally (Bhave et al., 2017). Carbenoxolone is used as
a medication for the treatment of peptic ulcers and inflammation. Interestingly, a study concluded
that negligible amounts of carbenoxolone cross the blood brain barrier; however, the researchers
only examined the cerebrospinal fluid and such data may not be representative for the actual brain
concentration (Leshchenko et al., 2006). Since carbenoxolone does not readily crossing the blood
brain barrier, this suggest a peripheral site of action.
The objective of this study, therefore, was to test the hypothesis that carbenoxolone
administered systemically would attenuate the development of morphine antinociceptive
tolerance. We report here that the systemic administration of carbenoxolone during the exposure
to morphine attenuates the development of antinociceptive tolerance to morphine. Further
investigation of the pharmacokinetics reveal that less than 3% of carbenoxolone found in the blood
was found in whole brain homogenates at several time points. Lastly, we observed whether invivo exposure of carbenoxolone would attenuate tolerance at the neuronal level in a cellular model
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of isolated dorsal root ganglia neurons from adult mice and whole cell patch clamp
electrophysiology

2. Materials and Methods
2.1. Animals
Male Swiss Webster mice (Harlan Laboratories, Indianapolis, IN) weighing 25–30 g were housed
five to a cage in animal care quarters and maintained at 22 +/- 2°C on a 12-hour light-dark cycle.
Food and water were available ad libitum. The mice were brought to the test room (22 +/- 2°C,
12-hour light-dark cycle), marked for identification, and allowed 18 hours to recover from
transport and handling. Protocols and procedures were approved by the Institutional Animal Care
and Use Committee (IACUC) at Virginia Commonwealth University Medical Center and comply
with the recommendations of the International Association for the Study of Pain (IASP).

5.2. Drugs and Chemicals
Morphine sulfate, 75-mg morphine pellets, and placebo pellets were obtained from the
National Institutes of Health National Institute on Drug Abuse (Bethesda, MD). Morphine sulfate
was dissolved in pyrogen-free isotonic saline (Hospira, Lake Forest, IL). Carbenoxolone was
obtained from Sigma-Aldrich Corporation (St Louis, MO, USA) and was dissolved in distilled
water.
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5.3. Antinociceptive Testing
Antinociception was assessed using the 52°C warm water tail withdrawal test performed
according to Coderre and Rollman (1983). Before injecting the mice, a baseline (control) latency
was determined. Only mice with a control reaction time from 2 to 4 seconds were used. Mice were
gently wrapped in a cloth and the distal one-third of the tail was immersed in a water bath. The
mice rapidly removed their tail from the bath at the first sign of discomfort and the tail-withdrawal
latency was recorded. Tail-withdrawal latency was then assessed using a cumulative dosing
procedure. Mice were injected with a starting dose of morphine and were tested for antinociception
20 min later. Mice that did not reach a 10 sec cut-off threshold received an additional cumulative
dose of morphine and were retested. This process was repeated until the animals reached the cutoff value of the 10-second maximum cut-off time imposed to prevent tissue damage.
Antinociception was quantified according to the method of Harris and Pierson (1964) as the
percentage of maximum possible effect (%MPE), which was calculated as: %MPE = [(test latency
– control latency) / (10 – control latency)]* 100. Percent MPE was calculated for each mouse.
Antinociception was also assessed using the 56°C hot plate assay. The hot plate test was
performed as described by Smith et. al. (2006). The mice were first placed on a Syscom Model
35D hot plate set at 56 °C to obtain baseline latencies before drug administration. The mice were
observed for licking their hind-limb or jumping in response to the heat. The mice were tested again
at the appropriate time after being administered test drugs. A 30 second cut-off was employed in
order to prevent tissue damage. Antinociception was quantified according to the method of Harris
and Pierson (1964).
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5.4. Tolerance Studies
Prior to all behavioral testing, mice were acclimated to the testing room for 24 h. For
assessments of morphine tolerance, mice received subcutaneous implants of placebo or morphine
pellets. Isoflurane (2.5%) was used to anesthetize the mice after which the hair on the back of the
neck was shaved. Povidone iodine (10%) and ethanol (70%) was used to clean the bare skin. A 1cm transverse incision was made into the subcutaneous space toward the dorsal flan with sterile
surgical instruments, and a placebo/ morphine pellet was placed distal to the incision. The incision
was closed with sterile autoclips. Mice were allowed to recover in their home cages after the
surgery and assessed every 48 h for signs of infection and weight loss. Five days later, mice were
assessed for morphine tolerance in a warm-water tail-withdrawal assay. To test carbenoxolone’s
ability to attenuate opioid tolerance, carbenoxolone was administrated intraperitoneally once per
day on days 3 & 4. This injection procedure was based off of a previous publication where
prolonged exposure to morphine would induce inflammation starting at days 3 and 4 of morphine
pellet implantation. Carbenoxolone administration on these days would prevent morphine induced
inflammation (Bhave et al., 2017b).

5.5. Analysis of Carbenoxolone levels in Brain and Blood
Seven-point calibration curves of Carbenoxolone at concentrations of 10 -1000 ng/mL for blood
and 10 – 1000 ng/kg for brain tissue homogenate and negative controls with or without internal
standard (ISTD) were prepared in drug-free mouse blood and brain tissue with each analytical run.
Carbenoxolone was extracted from blood and brain tissue homogenate using a modified Poklis et
al method (Poklis et al., 2011). In brief, the ISTD, 100ng of 11-Nor-9-carboxy-Δ9-
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tetrahydrocannabinol-d3 (THC-COOH-d3), was added to aliquots of 100 µL of blood or 400 µL
of homogenized brain tissue calibrators, controls and samples. These samples were mixed and
allowed to equilibrate. 1 mL of ice-cold acetonitrile was added drop by drop to each sample while
vortex mixing. The samples were then centrifuged at 3500 rpm for 10 min. After centrifuging the
samples were placed in –40°C freezer for at least 2 h. The top layer containing the acetonitrile was
removed via a disposable glass pipette and placed in a clean test tube. Samples were dried using a
Savant AES1000. The samples were reconstituted with 100 μL of acetonitrile and placed in auto
sampler vials for analysis.
The Ultra performance liquid chromatography tandem mass spectrometer (UPLC-MS/MS)
analysis of AEA, 2-AG, PEA OEA and arachidonic acid was performed on a Sciex 6500 QTRAP
system with an IonDrive Turbo V source for TurbolonSpray® (Sciex, Ontario, Canada) attached
to a Shimadzu UPLC system (Kyoto, Japan) controlled by Analyst software (Sciex, Ontario,
Canada). Chromatographic separation of Carbenoxolone and the ISTD, THC-COOH-d3, was
performed using a Zorbaz eclipse XDB-C18 column, 4.6 x 75 mm, 3.5 micron (Agilent
Technologies, USA). The mobile phase contained water/methanol (10:90, v/v) with 0.1 mM
ammonium formate and was delivered at a flow rate of 1 mL/min. The source temperature was set
at 650°C, and curtain gas had a flow rate of 30 mL/min. The ionspray voltage was 5000 V, with
the ion source gases 1 and 2 having flow rates of 60 mL/min. The acquisition mode used was
multiple reaction monitoring (MRM). The following transition ions were monitored in negative
mode: 569> 469 & 569> 425 for Carbenoxolone and 346> 302 & 346> 289 for THC-COOH-d3.
The total run time for the analytical method was 3.5 minutes.
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5.6. Isolation and Culture of Neurons from Adult Mouse Dorsal Root Ganglia
Mice were sacrificed by cervical dislocation. L5-S1 DRGs were immediately harvested
under a dissecting microscope and placed in a dish containing cold (4 °C) Hanks’ Balanced Salt
Solution (HBSS, ThermoFisher Scientific, Waltham, MA). Ganglia were incubated (37 °C) for 18
min in HBSS with 15 U/ mL papain, washed, and incubated for 60 minutes in HBSS with 1.5
mg/mL Clostridium histolyticum collagenase. After incubation, ganglia were transferred to
DMEM in a sterile 15mL conical, dissociated by triturating and centrifuged for 5 min at 1000 rpm.
The supernatant was discarded and the pellet was re-suspended in neurobasal A media containing
1% fetal bovine serum, 1x B-27 supplement, 10 ng/mL GDNF, 2mM L-glutamine and 100 U/ml
penicillin/streptomycin/amphotericin B (complete neuron media). Isolated cells were plated on
laminin and poly-D-lysine-coated glass cover slips and maintained at 37°C in a humidified 5%
CO2/air incubator.

5.7. Electrophysiology
Coverslips were transported to a microscope stage plate and continuously superfused with external
physiologic saline solution (PSS) containing (in mM) 135 NaCl, 5.4 KCl, 0.33 NaH2PO4, 5
HEPES, 1 MgCl2, 2 CaCl2, and 5 glucose. A GΩ seal was achieved via pulled (Model P-97
Flaming/Brown Micropipette Puller, Sutter Instruments, CA) and fire-polished (2–4 MΩ)
borosilicate glass capillaries (World Precision Instruments, Sarasota, FL) filled with internal PSS
containing (in mM) 100 L-aspartic acid (K salt), 30 KCl, 4.5 Na2ATP, 1 MgCl2, 10 HEPES, and
0.1 EGTA. DRG nociceptors being of the small, C and Aδ fiber types (Jin et al., 2013), only low
capacitance ( < 30 pF) neurons were selected for analysis. Standard patch clamp techniques were
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performed using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) and associated
Clampex and Clampfit 10.2 soſtware. Current clamp step protocols consisting of a 0 nA resting
current and 0.01 nA steps from − 0.03 nA were employed to assess passive and active cell
properties. Taking the derivative of the voltage with respect to time (dV/dt), threshold potentials
were defined as the voltage at which dV/dt significantly deviated from zero in the course of an
action potential uprise. For morphine tolerance studies, external PSS was supplement with 3 µ M
morphine and threshold potentials recorded at 1 min intervals for 10 min. The maximal effect of
morphine was recorded for each cell.
5.8. Statistical Analysis
Morphine dose-response curves were generated for calculation of ED50 values using leastsquares linear regression analysis followed by calculation of 95% confidence limits (95% CL) by
the method of Bliss (Bliss, 1967). All data are represented as mean ± standard error of the mean.
Analyses were considered significant when p < 0.05. The Vt results were calculated by Student’s
paired t-test using GraphPad Prism 6.0 (GraphPad Software, Inc., La Jolla, CA). For group
comparisons, results were calculated by two-way ANOVA with Bonferroni post-hoc analyses and
an alpha level set to 0.05. The results are expressed as mean value ± SEM.

3. Results
3.1. Attenuation of Antinociceptive Tolerance Development to Morphine by Carbenoxolone
in Warm-Water Tail Withdrawal Assay
On the fifth day after either placebo or morphine pellet implantation, baseline latencies
were taken prior to cumulative dosing regimen with morphine. In a 52°C water bath, cumulative
morphine-dosing produced antinociception in the placebo pelleted mice commensurate with what
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we have previously observed (Hull et al., 2013; Fig.1A). Using the 5-day tolerance model,
morphine pellet implantation produced a significant rightward shift [morphine pellet/vehicle ED50
= 16.2 (95% CI: 13.3 –19.8) (Fig.1A). 12.5 mg/kg carbenoxolone did not significantly shift the
morphine dose response curve following morphine pellet implantation [morphine pellet/12.5
mg/kg CBX ED50 = 12.9 (95% CI: 9.3 –17.9) (Fig.1B). The administration of a higher dose of
carbenoxolone (25 mg/kg) significantly shifted the morphine dose response curve leftward, though
still significantly different from acute morphine [morphine pellet/25 mg/kg CBX ED50 = 7.5 (95%
CI: 5.8 – 9.6) (Fig.1C). 25 mg/kg carbenoxolone administered on days 3 and 4 of placebo pelleted
mice did not significantly influence the acute morphine antinociception [placebo pellet/vehicle
ED50 = 3.5 (95% CI: 3.0 – 4.2), placebo pellet/25 mg/kg CBX ED50 = 4.6 (95% CI: 4.1 – 5.2)]
(Fig.1C). At 37.5 mg/kg carbenoxolone, the morphine dose response curve was not significantly
different from the placebo pelleted + carbenoxolone treatment group while significantly different
from the morphine pellet/vehicle group [morphine pellet/37.5 mg/kg CBX ED50 = 5.91 (95% CI:
4.8 – 7.3) (Fig.1D). Carbenoxolone administered on days 3 and 4 of placebo pelleted mice did not
significantly influence the acute morphine antinociception [placebo pellet/vehicle ED50 = 3.5 (95%
CI: 3.0 – 4.2), placebo pellet/37.5 mg/kg CBX ED50 = 4.8 (95% CI: 3.7 – 6.0)] (Fig.1D).
Carbenoxolone administered 30 minutes before the acute dosing regimen of morphine did
not acutely reverse chronic morphine nor did it affect acute morphine antinociception [placebo
pellet/vehicle ED50 = 3.2 (95% CI: 2.2 – 4.7), placebo pellet/25 mg/kg CBX ED50 = 5.0 (95% CI:
4.0 – 6.5), [morphine pellet/vehicle ED50 = 10.3 (95% CI: 7.8 –13.6), morphine pellet/25 mg/kg
CBX ED50 =8.3 (95% CI: 6.2 – 11.3)] (Fig. 2.).
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3.2. Attenuation of Antinociceptive Tolerance Development to Morphine by Carbenoxolone
in Hot Plate Assay
To investigate the effect of carbenoxolone on supraspinal-mediated antinociception, we
performed the hot plate rear hind paw lick assay. On the fifth day after either placebo or morphine
pellet implantation, baseline latencies were taken prior cumulative dosing regimen of morphine.
On a 56°C hot plate, cumulative morphine-dosing produced antinociception in the placebo pelleted
mice [Placebo pellet/vehicle ED50 = 7.3 (95% CI: 5.8 – 9.2)]. Carbenoxolone administration on
days 3 and 4 of placebo pellet implantation did not significantly shift the antinociceptive properties
of morphine [Placebo pellet/25 mg/kg CBX ED50 = 7.5 (95% CI: 6.4 – 9.0)]. Exposure to chronic
morphine through pellet implantation produced significant tolerance as indicated by a significant
rightward shift [Morphine pellet/Vehicle ED50 =85.4 (95% CI 54.6 – 133.3)]. Carbenoxolone
administration attenuated morphine antinociceptive tolerance in the hot-plate assay [Placebo
pellet/25 mg/kg CBX ED50 = 35.1 95% CI: 25.8 – 47.6)] (Fig.3).
3.3. Carbenoxolone Does Not Readily Cross the Blood Brain Barrier
Although carbenoxolone was not observed in the cerebrospinal fluid in a previously
published study, the possibility remained that carbenoxolone sequesters within brain tissue.
Therefore, following an intraperitoneal injection of 25 mg/kg carbenoxolone, blood samples and
whole brains were taken from mice. Figure 4 shows that the UPLC-MS/MS-determined
carbenoxolone concentration in the blood samples at several time points. At the same time points,
less than 3% of carbenoxolone levels found in the blood were observed in the brain at all time
points tested (Fig. 4).
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3.4. Morphine Tolerance Attenuated by In Vivo Carbenoloxone Treatment in Sensory
Neurons from Dosrsal Root Ganglia.
To test whether the effects of carbenoxolone administration on morphine tolerance could
be recapitulated in single cells, dorsal root ganglion (DRG) nociceptors were isolated from spinal
levels supplying the lower alimentary canal (L5-S1). Candidate neurons were selected for their
round spherical shape and small size. Active and passive properties of low capacitance (<30 pF)
cells were measured from the DRG neurons of each group by whole-cell patch clamp techniques.
Neurons from placebo pelleted mice and neurons from morphine pelleted mice treated with
carbenoxolone responded to morphine challenge (3 µM) by a positive shift in the threshold
potential indicating morphine-induced reduction in excitability. The threshold potential was
determined from the derivative of the action potential (dV/dt) in the absence and presence of acute
morphine challenge. The thresholds of neurons from morphine pelleted mice treated with vehicle
did not respond to the morphine challenge, indicating the development of tolerance. (Fig. 5.). A
number of cell properties did not significantly vary between treatment groups or between baseline
and morphine exposure, including membrane capacitance, series resistance, input resistance,
rheobases, and resting membrane potential (Table 3; Appendix). PP + SAL and MP + SAL groups
have been previously published by our laboratory (Kang & Mischel et al., 2017).

87

Fig. 1. Carbenoxolone attenuates development of morphine tolerance as measured in warm
water tail withdrawal assay (A) 5 day morphine pellet implantation significantly shifted the ED50
for morphine to the right indicating tolerance (n = 15 / group). (B) 12.5 mg/kg Carbenoxolone
administered 1x per day on days 3 & 4 (n = 5) did not significantly shift the morphine pellet ED50.
(C) 25 mg/kg administered 1x per day on days 3 & 4, carbenoxolone significantly shifted the
morphine pellet curve leftward. (D) At the highest dose tested (37.5 mg/kg), carbenoxolone further
significantly shifted the morphine pellet curve leftward (n = 5). Carbenoxolone administered to
placebo pellet mice did not shift the acute morphine ED50.
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Fig. 2. Carbenoxolone does not acutely reverse morphine tolerance as measured in warm
water tail withdrawal assay 5 day morphine pellet implantation significantly shifted the ED50
for morphine to the right indicating tolerance (n = 5 / group). Pretreatment of 25 mg/kg
Carbenoxolone administered 30 min before challenge doses of morphine did not significantly
shift the morphine pellet ED50. Pretreatment of carbenoxolone administered to placebo pellet
mice did not shift the acute morphine ED50.
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Fig. 3. Carbenoxolone attenuates development of morphine tolerance as measured in hot
plate assay 5 day morphine pellet implantation significantly shifted the ED50 for morphine to the
right indicating tolerance (n = 15 / group). 25 mg/kg carbenoxolone administered 1x per day on
days 3 & 4 significantly shifted the morphine pellet curve leftward. Carbenoxolone administered
to placebo pellet mice did not shift the acute morphine ED50.
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Fig. 4. Brain and Blood concentrations of Carbenoxolone (mean +/- SEM) were observed at
different time points following a 25 mg/kg intraperitoneal injection in drug naïve mice. Less than
3% of carbenoxolone levels found in the blood were observed in the brain at all time points
tested
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Fig. 5. CBX on DRG neurons isolated from MP mice Collective data from threshold potential
(Vt) measurements before (open circle) and after (filled circle) morphine perfusion. Increases in
Vt induced by 3μM morphine perfusion are prevented by chronic morphine exposure, but
preserved alongside CBX treatment. #PP + SAL and MP + SAL groups have been previously
published by our laboratory (Kang & Mischel et al., 2017). ns not significant, ***p<0.001
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4. Discussion
Gap junctions are recognized as important contributors to intercellular communication.
Through gap junctions flow second messengers, ions, and metabolites, generating waves of
elevated calcium, sodium, and metabolic activity. Gap junctions exist on neurons but also have an
important role in glial cell networks. Gap junctions consist of connexins, with the name of
respective molecular weight. A number of studies indicate gap junctions having potential
involvement in inflammatory cascades as well involvement in mechanisms in pain. For example,
connexin 43 expression is increased in several neuropathic pain models including spinal cord
injury, chronic constriction injury, and neuroinflammation (Haupt et al., 2007; Lee et al., 2005;
O’Carroll et al., 2008). Administering gap junction inhibitors has been shown to attenuate
neuropathic pain sensitization caused by chronic constriction injury (Jeon and Youn, 2015; Spataro
et al., 2004). Gap junctions have also been shown to be involved in chronic morphine-induced
effects including colon inflammation, dependence, and antinociceptive tolerance (Bhave et al.,
2017b; Moradi et al., 2013; Shen et al., 2014). Astrocytic connexins in the spinal cord have been
reported to be integral for the development of morphine antinociceptive tolerance. Carbenoxolone
is a medication used to treat peptic ulcers in man and is also a known gap junction inhibitor. Studies
in the past investigating gap junction function in neuropathic pain mechanisms or chronic
morphine’s effects concentrated on administering carbenoxolone intrathecally through
intracerebroventricular injection (i.e. past the blood brain barrier).
In the present study, we observed carbenoxolone administered systemically attenuated the
development of opioid antinociceptive tolerance. Through intraperitoneal injections during the
exposure to chronic morphine, carbenoxolone was able to rescue morphine antinociceptive
tolerance seen in the warm water tail withdrawal assay (primarily a spinal reflex) and in the hot
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plate assay (primarily mediated by supraspinal mechanisms). Carbenoxolone did not affect acute
morphine antinociception. Examining whether carbenoxolone administered right before the
morphine challenge would affect tolerance, we observed that carbenoxolone was not able to
acutely reverse morphine antinociceptive tolerance in the warm water tail withdrawal assay.
Carbenoxolone has been shown to mitigate central and peripheral effects caused by chronic
exposure to morphine. However, the molecule of carbenoxolone is polar and relatively large which
raises the question as to its ability to cross the blood brain barrier. One study examined
carbenoxolone levels in cerebral spinal fluid (CSF) of rats after intraperitoneal injection. The
researchers observed “negligible levels” (<1 µM) of carbenoxolone in CSF (Leshchenko et al.,
2006). However, a major caveat of that study was that the drug potentially concentrated itself
within brain tissue with little in the CSF. We developed a technique using UPLC-MS/MS in order
to analyze carbenoxolone in whole brain tissue from mice. Less than 3% of the carbenoxolone
levels found in blood was observed in the brain at any time point investigated. Whether the small
amount of carbenoxolone observed in the brain tissue is biologically significant is unknown.
However, the whole brain tissue was dissected and homogenized for this study. This dissection
and homogenization would include some amount of blood vessels which may explain the small
amount of carbenoxolone detected.
The evidence supporting carbenoxolone’s inability to cross the blood brain barrier suggests
a peripheral site of action. The dorsal root ganglia contain the cell bodies of primary afferent
neurons that act as a “relay station” transmitting sensory information from the periphery into the
CNS. DRGs sit in the periphery just outside the blood brain barrier alongside the spinal cord. It
has been well established that MORs are expressed in DRG neurons and it has been suggested that
peripheral mechanisms are important for the development of opioid antinociceptive tolerance.
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Deletion of MOR specifically on afferent nociceptors eliminated antinociceptive tolerance in mice
while antinociception was unaffected (Corder et al., 2017). This suggests that the analgesic effects
of morphine are mediated centrally while peripheral effects are playing a role in tolerance
development. In the DRGs, satellite glial cells (SGCs) completely wrap around the sensory
neurons. This arrangement allows SGCs to regulate ion concentration in the extracellular space,
recycle neurotransmitters, and facilitate non-synaptic communication between neurons and glia
(Gu et al., 2010; Suadicani et al., 2010). The signaling that occurs between neurons and SGCs
involve gap junctions and this communication can be interrupted by the use of a gap junction
inhibitor such as carbenoxolone (Suadicani et al., 2010). We have since published that tolerance
to opioids can be evaluated in DRGs (Jacob et al., 2018; Kang et al., 2017). With this model, we
observed that tolerance developed to morphine on a neuronal level with the same 5-day morphine
pellet in-vivo treatment as done with the tail withdrawal and hotplate assays. Furthermore, 25
mg/kg carbenoxolone administered on days 3 and 4 of chronic morphine exposure restored the
neurons’ ability to respond to a morphine challenge, indicating that tolerance did not develop. This
suggests a possible peripheral mechanism by which carbenoxolone is able to exert its attenuation
of antinociceptive tolerance effects.
Although these results are intriguing, additional issues need further investigation. The most
important issue with interpreting the effects of gap junction blockers such as carbenoxolone is that
in addition to gap junctions, they affect various ion channels, receptors and enzymes. Therefore, it
would be important to compare the behavioral effects of different gap junction blockers with
results obtained in knockout mice for specific types of gap junctions. In addition, carbenoxolone
which has been shown to block gap junctions but also shown to block NMDA receptors and block
calcium channels at higher concentrations (Chepkova et al., 2008; Vessey et al., 2004). These
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targets have been implicated in opioid antinociceptive tolerance (Allen et al., 2000; Dogrul et al.,
2005; Tiseo and Inturrisi, 1992; Trujillo and Akil, 1991). A study examining carbenoxolone
metabolism noted that carbenoxolone hydrolysis in mammalian tissues does not appear to occur
and most of carbenoxolone metabolism occurs due to the microflora of the stomach and small
intestine (Iveson et al., 1971). This suggests that active metabolites should not be a concern from
an intraperitoneal injection however further studies should examine carbenoxolone’s metabolites,
their possible effects, and ability to cross the blood brain barrier.
The notion that gap junctions may be involved in opioid tolerance has been suggested from
previous studies. Initial work demonstrating that microglia and astrocyte activation occurs as a
result of chronic morphine treatment has been followed by demonstration of chronic opioid
induced upregulation of connexins in astrocytes alongside the development of tolerance.
Administering a gap junction blocker intrathecally attenuated the development of antinociceptive
tolerance (Shen et al., 2014). Our study shows that gap junctions playing an important role in the
development of opioid antinociceptive tolerance while also suggesting a potential peripheral
target. Further work is needed to determine whether gap junctions on neurons or glia cells are
integral for the development of opioid tolerance and if a certain type of connexin plays a leading
role in this effect.
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CHAPTER 5
GENERAL DISCUSSION
Historically, the relief of moderate to severe pain was primarily managed by treatment
utilizing opioid analgesic medications. However, hesitation exists to prescribe these medications
due to the side effects that are associated with repeated use of these compounds. Repeated exposure
to opioids can lead to tolerance to its desired effects, leading to a cycle of increasing doses
accompanied by increased occurrence of side effects such as respiratory depression, constipation,
dependence, in addition to addiction. This creates problems not only in clinical populations but
also abusers as well. Clinically, opioids are often used in tandem with other medications and in
different disease states. Outside the clinic, opioid abusers tend to be polydrug abusers, consuming
a number of different substances often at the same time. In both cases, a variety of serious health
complications can occur, many not fully understood. The objective of this dissertation was to
investigate some of the complexities of chronic opioid exposure and how different disease states
and medications may modulate the effects of chronic opioids. The studies described here lead to
new understandings of what occurs on a behavioral and cellular level during repeated exposure to
opioids.
In our first series of experiments, we investigated the increasing occurrence of
benzodiazepine use alongside the prescription opioid epidemic. Benzodiazepines are among the
most frequently prescribed medications in the world (Coach Jr., 1990). They are commonly
prescribed for the treatment of anxiety disorders. Research suggests that the abuse liability of
benzodiazepines is especially notable in recreational users of other drugs (Jones et al., 2012).
Additionally, patients maintained on opioid agonists such as methadone and buprenorphine, as
well as active heroin users, tend to abuse benzodiazepines (Barnas et al., 1992; Brands et al., 2008;
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Darke et al., 1995, 1992; Kleber and Gold, 1978). One study investigating heroin users in Australia
showed that 2 out of 3 heroin users reported nonmedical benzodiazepines use within the past year,
and 91% reported a lifetime prevalence (Ross and Darke, 2000). Furthermore, opioid-dependent
populations show a preference for particular benzodiazepines. One of the most commonly
coabused benzodiazepine in these populations is diazepam (Bramness and Kornør, 2007; Du Pont,
1988; Iguchi et al., 1993). Whether the co-abuse of opioids and benzodiazepines stem from
underlying psychiatric disorders (i.e. anxiety), aiding with dependence, or increasing the rewarding
and reinforcing effects remains to be determined. However, studies have shown individuals may
be using benzodiazepines to amplify the positive effects of opioids. For example, one study
reported that 72% of methadone-maintained patients who were regular benzodiazepine users
indicated that diazepam enhanced the effects of their daily methadone dose (Stitzer et al., 1981).
In 2016, the Food and Drug Administration issued a black-box warning about coprescribing benzodiazepines and opioids. Among the data reviewed by the FDA, the agency
concluded that from 2004 to 2011, the rate of emergency department visits involving non-medical
use of both drug classes increased significantly, with overdose deaths involving both drug classes
nearly tripling during that period. Studies have observed an increased effect of respiratory
depression when benzodiazepines are administered intravenously (Carraro et al., 2009; Zacharias
et al., 1996). It has yet to be determined how benzodiazepines may affect opioid tolerances, if it is
simply additiveness or something more. Our observations suggest this phenomenon may not be
simply due to the additive or synergistic of these CNS depressants but instead results from a
reversal of opioid tolerance. Diazepam, at doses tested, did not induce any antinociceptive effects
on their own nor did they potentiate acute doses of the commonly prescribed opioids oxycodone
or hydrocodone. However, in an opioid tolerant state, diazepam rescued the antinociceptive effect
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of both oxycodone and hydrocodone, enabling the opioids to produce antinociception at doses
similar to those observed in a mouse acutely treated with morphine. This reversal of tolerance
effect extends to locomotor tolerance as well. Commonly described as a depressant, diazepam was
able to rescue the increased locomotor effects commonly seen by opioids administered to drugnaive mice.
Although not tested in this series of experiments, a previous publication from our
laboratory showed similar reversal of tolerance for morphine, a partial μ-agonist like oxycodone
and hydrocodone. That work showed that the reversal of tolerance effect of diazepam was blocked
by the GABAA antagonist bicuculline, suggesting that diazepam is enacting these effects through
GABAA. Benzodiazepines act as positive allosteric modulators of the GABA A receptors.
Benzodiazepines act to enhance the effects of GABA by increasing chloride flux and rate of
channel opening. In terms of circuitry, it has been theorized that both benzodiazepines and opioids
produce a hyperpolarization of GABA interneurons which causes a reduction in the release of
GABA which results in the disinhibition of dopaminergic neurons and an increase in extracellular
dopamine in areas such as the striatum (Tan et al., 2011). Opioid-induced locomotion is due to mu
opioid receptor-mediated increases in striatal dopamine release (Johnson and Glick, 1993; Kalivas
and Duffy, 1987; Piepponen et al., 1999). GABAergic interneurons also play an important role in
opioid antinociception (Lau et al., 2014). This suggests the GABAA receptor as a potential site of
action that should be further characterized.
People who suffer from addiction often have one or more accompanying medical issues
including infectious diseases. Concurrent with the opioid abuse epidemic, almost 40,000 people
were diagnosed with HIV infection in the United States in 2015 (CDC, 2016). Opioid abuse and
the spread of HIV are intertwined public health epidemics. Worldwide, injection drug use (IDU)
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accounts for ~30% of new HIV-1 infections while within the United States, over 3,500 new
infections involved IDU in 2015 (WHO, 2016; CDC, 2016). Among non-addicts, HIV-related pain
may necessitate opioid analgesics. These populations face special risks because a number of
studies have uncovered evidence that opioid usage increases the progression of HIV-1 to AIDS
and promotes neurocognitive impairment in humans and in non-human primates (Bell et al., 2006,
2002; Bokhari et al., 2011; Chuang et al., 2005; Donahoe et al., 1993; Kumar et al., 2006; R et al.,
2004; Rivera et al., 2013). Furthermore, studies have shown that the HIV-1 regulatory protein Tat
can be secreted from infected cells to exert direct and indirect neurotoxicity by promoting
neuroinflammation (reviewed in King et al., 2006; Nath et al., 2002). Even with the recent
innovative antiretrovirals that have made HIV treatable but not yet curable, Tat may sequester in
regions of the brain to nearly undetectable levels and still cause neuroinflammation (Hellmuth et
al., 2015). As previously mentioned, in vitro studies have shown that morphine exacerbates Tat
effects to activate microglia, increase cytokine production, drive oxidative stress, increase
intracellular calcium, and promote neurotoxicity. Morphine and Tat interactions may depend on μ
opioid receptors (MORs) given that neurotoxic synergy is observed in co-cultures when mixed
glia express MORs, but not when they are derived from MOR−/− mice (Zou et al., 2011). These
data support the notion that glial MORs are critical for the indirect neurotoxic effects of Tat.
The proinflammatory effects of HIV-1 Tat at CCR5 have been reported to directly
influence opioid sensitivity. In studies of opioid-mediated antinociception in rats, activation of
CCR5 can rapidly desensitize μ-opioid-receptors (Chen et al., 2007). A bivalent ligand comprised
of an opioid receptor antagonist (naltrexone) and CCR5 antagoinist maraviroc reduced the
infectivity of human astrocytes when cultured with R5-tropic HIV (Arnatt et al., 2016; El-Hage et
al., 2013; Yuan et al., 2013). These data suggest a dynamic relationship between MOR and CCR5
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activation that may contribute to HIV pathology; however, the functional effects are poorly
understood. As such, we investigated morphine tolerance, dependence, and reward in a transgenic
murine model that conditionally expresses the proinflammatory HIV-1 regulatory protein, Tat. We
demonstrated that pretreatment with the CCR5 antagonist, maraviroc, blocks the effects of Tat on
morphine tolerance and dependence behaviors (reinstating morphine potency in non-tolerant mice
and restoring aspects of withdrawal symptomology in morphine tolerant mice). Intriguingly,
maraviroc also potentiated the Tat-induced increase of morphine-CPP, even while it reduced the
levels of many inflammatory chemokines and cytokines in the striatum including β-chemokines.
Interestingly, Tat was able to attenuate the antinociceptive properties of acute morphine in opioidnaïve mice. Maraviroc administered to Tat + mice rescued the antinociceptive properties of
morphine. We proposed a possible model of cross-desensitization that may contribute to the
behaviors observed. When a neuroinflammatory insult, in the form of Tat, is present, morphine
potency is diminished on most measures, perhaps due to endogenous MORs becoming crosssensitized by activated CCR5 receptors. When maraviroc is introduced to block the CCR5
receptors, we speculate that it may relieve the cross-sensitization of MORs, restoring morphine
signaling. While cross-desensitization of MOR and CCR5 is fairly well documented in vitro and
is seemingly due to phosphorylation of the receptors, the intracellular kinases responsible have yet
to be determined. However in a 2005 study, researchers observed PKC playing an integral role in
the cross-desensitization occurring among different chemokine receptors (including CCR5). It has
been often reported that PKC play an important role in MOR desensitization in vitro and in both
respiratory depressive and antinociceptive tolerance after repeated exposure to morphine and other
opioids (Bailey et al., 2009, 2006; Hill et al., 2018; Hull et al., 2010; Jacob et al., 2018; Lin et al.,
2012; Llorente et al., 2013; Smith et al., 1999). This suggests that activating CCR5 due to the Tat
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inflammatory insult may be activating PKC downstream. This may preemptively desensitize
MORs, behaviorally seeming like tolerance even though subjects are naïve to opioids. Future
studies should examine whether Tat’s attenuation of certain effects of morphine is due to
intracellular processes involving PKC.
As mentioned previously, glial MORs appear to be critical for the indirect neurotoxic
effects of Tat. Studies have shown that in astrocytes, significant changes in gene expression,
apoptosis, glutamate metabolism, and blood brain barrier have been reported, suggesting that these
cells play a key role in NeuroAIDS (Berman et al., 2016; Eugenin et al., 2011; Wang et al., 2004).
A major component of astrocytes and other glial cells are gap junctions, which are channels that
connect the cytoplasmic compartment a cell to other cells or into the extracellular space and allow
electrical and secondary messenger based communication to occur. However, HIV infection of
astrocytes results in opening of hemichannel and increases the amount of hemichannel present
particularly connexin 43 (Berman et al., 2016). HIV-Tat protein has been implicated as directly
promoting the increase in connexin upregulation, however a recent publication shows the mere
exposure of HIV-Tat in the colon of rats causes an inflammatory cascade through connexin 43
upregulation going up the spinal cord into the brain with no detectable HIV-Tat in the CNS
(Berman et al., 2016; Esposito et al., 2017). Blocking gap junctions using carbenoxolone
significantly reduced HIV infection of human-derived pericytes (Cho et al., 2017). Another recent
study shows that gap junctions are integral for HIV-induced toxicity (Malik et al., 2017).
Upregulated gap junction expression and function, particularly connexin 43, has been associated
with chronic exposure to morphine including morphine tolerance (Bhave et al., 2017a; Moradi et
al., 2013; Shen et al., 2014). Therefore, we tested the hypothesis that carbenoxolone, a gap junction
inhibitor, administered systemically would attenuate the development of morphine antinociceptive
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tolerance. We observed that carbenoxolone was able to attenuate the development of morphine
antinociceptive tolerance in a dose-dependent manner. Carbenoxolone given acutely before
challenge doses of morphine did not affect morphine antinociception nor did it acutely reverse
antinociceptive tolerance. In an attempt to identify a possible site of action where carbenoxolone
may produce its effects, we demonstrated that carbenoxolone is not observed in brain tissue after
intraperitoneal injection, suggesting an effect in the periphery. Subsequently, we observed that
carbenoxolone administration in vivo during chronic exposure to morphine attenuated the
development of tolerance in neurons isolated from dorsal root ganglion. Peripheral mechanisms
for antinociceptive have been suggested in the past (Corder et al., 2017; Kang et al., 2017; Puig
and Gutstein, 2017). Future studies should examine the location (neuronal or glial) and what type
of gap junctions (i.e. connexin 43) are necessary for this effect to occur. This can be performed
using specific connexin knockouts inducible on neurons or glial cells.
Collectively, the studies in this dissertation have increased our knowledge of the
interactions between chronic opioids and different medications and disease states. The compounds
diazepam, maraviroc and carbenoxolone highlight the complexities of how chronic opioid effects
such as tolerance manifest and can be modulated. At the same time, these compounds teasingly
point to mechanisms that may be shared by chronic opioid exposure. For instance, GABAergic
interneurons play a pivotal in pain circuity as well as in opioid’s analgesic effects from CNS areas
such as the PAG and dorsal horn spinal cord (Lau et al., 2014). Timely activating GABAA receptors
in DRGs after peripheral nerve injury has been shown to attenuate the development of neuropathic
pain (Naik and Pathirathna, 2008). As previously shown, activating GABAA receptors reversed the
development to opioid antinociceptive tolerance (Hull et al., 2013). Specifically where in the body
this occurs should be examined in future studies. Chronic opioids are known to activate glial cells
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including astrocytes, microglia, and satellite glia (Shen et al., 2014; Song and Zhao, 2001). Glia
play an important role in the regulation of GABA reuptake (Allison et al., 2011). An integral
component of glia activation and resulting communication with neurons are through gap junctions.
We and others have shown that gap junctions appear to play a role in the development of opioid
tolerance and other opioid mediated effects (Moradi et al., 2013; Shen et al., 2014). Glial cells are
also important mediators of inflammation. Inflammatory insults including TNF-α, IL-1β, and IL6 have been associated with chronic morphine exposure and with opioid tolerance (Shen et al.,
2012). Inflammatory cytokines activating CCR5 can cross-desensitize MOR through a
phosphorylation mechanism that, although experimental evidence is lacking, may involve PKC, a
kinase that has been implicated in opioid tolerance. The interactions between these components
warrant future experiments in order to elucidate the specific pathways by which opioids enact their
acute and chronic effects.
With the overprescription of opioid analgesics as well as the availability of potent heroin,
the opioid epidemic has grown to unprecedented heights in the past decade. Consequently, more
people are chronically exposed to opioids. Studies on repeated exposure to opioids have been done
for decades yet the mechanisms for certain phenomena such as tolerance are still not fully
understood. Furthermore, different medications, such frequently prescribed benzodiazepines, or
different disease states, such as HIV, have their own effects and interactions with chronic opioid
exposure that are not fully examined. The present findings add to the body of literature by
investigating the consequences of these interactions on opioid-mediated effects especially
antinociceptive tolerance while highlighting potential components that play a role in opioid
tolerances.
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Appendix A
Table 3: Active and Passive Cell Properties of DRG Neurons in Response to 3μM Morphine
+ 3 uM
+ 3 uM
MP + CBX
+ 3 uM
PP + Saline #
MP + Saline #
#
#
Morphine
Morphine
Morphine
CMem (pF)
18.5 ± 1.6
15.8 ± 1.9
Rseries (MΩ) 8.6 ± 0.8
9.1 ± 0.8
VRest (mV)
−58.2 ± 1.6 −57.0 ± 2.1 −58.8 ± 2.8
AP VThresh
−13.2 ± 2.1 −3.4 ± 4.3*** −20.7 ± 2.3
(mV)
AP VPeak
51.6 ± 6.0
53.4 ± 5.6
43.3 ± 6.4
(mV)
Rheobase
0.15 ± 0.06 0.21 ± 0.07 0.05 ± 0.02
(nA)

−59.8 ± 2.8

21.0 ± 1.7
10.8 ± 2.1
−55.0 ± 1.4

−21.6 ± 3.2

−16.6 ± 2.2 −11.8± 2.1***

58.0 ± 3.4

56.1 ± 3.4 59.5 ± 6.3

0.03 ± 0.01

0.23 ± 0.02

−53.4 ± 1.3

0.3 ± 0.05

RInput (MΩ) 479.4 ± 158.3 257.5 ± 62.8 422.8 ± 132.2 671.7 ± 41.67 413.9 ± 56.4 382.5 ± 63.4

Table 3. Changes in various parameters were analyzed at baseline (0 minutes) and 10 minutes
following the application of an external solution containing 3μM morphine. Threshold potential
(VThresh) was significantly reduced in response to morphine in all treatment groups except in
the neurons isolated from the morphine pelleted mice. Membrane capacitance (CMem), resting
membrane potential (VRest), peak action potential height (AP VPeak), rheobase, and input
resistance (RInput) were all unaffected by 3 μM morphine. #PP + SAL and MP + SAL groups
have been previously published by our laboratory (Kang & Mischel et al., 2017). ***p<0.001
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